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As more people are surviving into 
more advanced ages, prevention of 
dementia is now a major public health 
challenge. Recent findings showing 
that several lifestyle and health-related 
risk factors may increase the risk 
of for dementia and its major cause, 
Alzheimer’s disease (AD), has been of 
special interest because many of these 
risk factors are potentially modifiable. 
This thesis investigated putative risk 
factors for dementia and AD that have 
not been previously indepth studied: 
smoking and common pulmonary and 
heart diseases, in two cohort studies 
with the baseline at midlife and a long 
follow-up time of over two decades.
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ABSTRACT
As more people are surviving into more advanced ages, prevention of dementia is now a 
major public health challenge. Data on several cardiovascular and lifestyle related factors as 
a risk factor for dementia have been accumulating during the recent years. The present thesis 
focuses on putative risk factors for dementia and its major cause, Alzheimer’s disease (AD), 
and cognitive impairment that have not been previously indepth studied: smoking and com-
mon pulmonary and heart diseases. The project aimed to add to the current knowledge on the 
complex puzzle of risk factors of AD.
Three studies (study I, III and IV) of the present thesis are based on the Finnish Cardiovascular 
Risk Factors, Aging and Dementia (CAIDE) study. CAIDE is a population-based study inves-
tigating cardiovascular and lifestyle related risk factors for dementia and cognitive function-
ing. Participants (n=2000) were derived from independent, random, population-based samples 
studied in 1972, 1977, 1982, or 1987. Re-examinations of the cohort have been carried out in 1998 
and in 2005-2008. Altogether 1511 (75.6 %) individuals participated in the re-examinations. 
Study II was based on a retrospective cohort (n= 21 123) of members of the Kaiser Permanente 
Medical Care Program of Northern California. The participants were examined once at midlife, 
and dementia diagnoses were ascertained from electronic medical record database on average 
23 years later.
This series of studies showed that smoking in midlife increases the risk of dementia and 
its major subtypes, AD and vascular dementia, later in life. The risk may be especially pro-
nounced among persons carrying one susceptibility gene to AD, apolipoprotein E (APOE) ε4. 
The presence of two common pulmonary diseases, chronic obstructive pulmonary disease 
(COPD) and asthma, at midlife were also associated with an increased risk of cognitive im-
pairment in late-life. However, pulmonary diseases not diagnosed until late-life were inversely 
associated with cognitive impairment. Heart diseases are common among the elderly, and this 
study indicates that especially atrial fibrillation in late-life may increase the subsequent risk 
of dementia and AD. Heart diseases diagnosed already in midlife did not increase the risks, 
except among the APOE ε4 carriers with heart failure who were at an increased risk of AD. 
The present set of results provide another reason for quitting smoking or never starting the 
habit, and also suggest that prevention and treatment of pulmonary and heart diseases may 
be important also from the perspective of brain health and cognitive functioning. The current 
data improve our understanding that dementia results from many, partly modifiable, risk fac-
tors, not all of which necessarily affecting directly the brain itself.
National Library of Medical Classification: WT 155, WT 150, WM 220, WL 358.5, WA 105
Medical Subject Headings: Dementia; Alzheimer Disease; Mild Cognitive Impairment; 
Epidemiology; Risk Factors; Smoking; Lung Diseases; Heart Diseases; Apolipoprotein E4    
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TIIVISTELMÄ
Väestön ikääntyessä dementiaa sairastavien henkilöiden määrä tulee kasvamaan räjähdysmäis-
esti, ja tämän uhkakuvan valossa dementian ennaltaehkäisyllä on nyt ja tulevaisuudessa erit-
täin merkittävä kansanterveydellinen ja -taloudellinen merkitys. Tähän mennessä on löydetty 
vain joitakin dementian riskitekijöitä, joihin voidaan aikaisella hoidolla tai ennaltaehkäisevällä 
työllä vaikuttaa. Tämän väitöskirjatyön tarkoituksena oli selvittää tupakoinnin sekä yleisten 
keuhko- ja sydänsairauksien vaikutusta kognitiivisen heikentymisen ja dementian kehitty-
miseen. 
Kolme osatutkimusta (I, III ja IV) pohjautuvat suomalaiseen Kardiovaskulaariset riskiteki-
jät, ikääntyminen ja dementia (CAIDE) tutkimukseen. CAIDE –tutkimuksen (n=2000) osallis-
tujat on poimittu satunnaisesti Pohjois-Karjala projektin ja FINMONICA tutkimuksen neljään 
itsenäiseen väestöotokseen vuosina 1972, 1977, 1982 ja 1988 osallistuneista henkilöistä. Yli 20 
seurantavuoden jälkeen 1511 (75.6 %) henkilöä osallistui CAIDE –tutkimuksen seurantakäyn-
neille vuosina 1998 ja 2005-2008. Väitöskirjan toinen osatutkimus pohjautuu yhdysvaltalai-
seen retrospektiiviseen, monietniseen tutkimuskohorttiin (Kaiser Permanente of Northern 
California). Henkilöt (n=21 123) osallistuivat vuosina 1978-1985 vapaaehtoiseen terveystarkas-
tukseen ja keskimäärin 23 seurantavuoden jälkeen sähköisestä sairauskertomusjärjestelmästä 
selvitettiin kuinka moni oli sairastunut dementiaan. 
Tutkimus osoitti, että tupakointi keski-iässä lisää myöhempää riskiä sairastua dementian 
yleisimpiin muotoihin Alzheimerin tautiin (AT) ja verisuoniperäiseen dementiaan. Riski oli 
erityisen suuri henkilöillä, joilla on perimässään AT:n yleinen riskigeeni apolipoproteiini E 
(APOE) ε4. Myös keski-iässä diagnosoitu keuhkoahtaumatauti ja astma olivat yhteydessä 
myöhempään kognitiiviseen heikentymiseen. Sairastuminen näihin keuhkosairauksiin vasta 
myöhemmällä iällä oli käänteisesti yhteydessä kognitiiviseen heikentymiseen. Lisäksi tutki-
mus osoitti, että ikääntyvien yleiset sydänsairaudet, erityisesti eteisvärinä, lisäävät myös ris-
kiä sairastua dementiaan ja AT:iin. Kuitenkin jos sydänsairaus oli todettu jo keski-iässä, aino-
astaan sydämen vajaatoiminta APOE ε4 –kantajilla oli yhteydessä myöhempään AT:n riskiin. 
Tulokset osoittavat, että tupakoinnin välttäminen sekä keuhko- ja sydänsairauksien hyvä 
hoito saattaa ehkäistä dementiaa. Vaikuttaa todennäköiseltä, että geneettisten ja elämänta-
patekijöiden lisäksi myös muut sairaudet vaikuttavat dementiariskiin, ja näiden hyvä hoito 
yhdistettynä terveisiin elämäntapoihin voi auttaa dementian ehkäisyssä. 
Luokitus: WT 155, WT 150, WM 220, WL 358.5, WA 105
Yleinen suomalainen asiasanasto: dementia; Alzheimerin tauti; muistisairaudet; epidemiologia;
riskitekijät; tupakointi; keuhkosairaudet; sydäntaudit; apolipoproteiinit
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1 Introduction
Thanks to the previous and ongoing epidemiological studies, the big picture illustrating the 
risk factors and development of dementia and Alzheimer’s disease (AD) has become clearer 
during recent years. A specific challenge in Alzheimer research is that AD has a very long pre-
clinical phase with a progressive disease pathology development in the brain which goes on 
for even decades before the first clinical symptoms appear (Braak et al. 1999, Ohm et al. 1995). 
Risk factors measured in midlife may better predict dementia in late-life because they are less 
affected by the disease process. Therefore long, detailed epidemiological studies which investi-
gate the putative risk factors for dementia and AD already in midlife are crucial in identifying 
the constitutive risk factors which may trigger the onset as well as contributing to the devel-
opment of the disease. In this way, it will be possible to understand more comprehensively 
the pathophysiological mechanisms of this complex disease, and furthermore, in the future 
hopefully prevent or at least delay its onset. In view of the increasing longevity of populations 
worldwide, prevention of dementia has turned into a major public health challenge. The cur-
rent study is an overview of the risk factors of dementia and AD and cognitive impairment 
focusing on three major issues not previously widely studied: a very common lifestyle related 
risk factor smoking and major comorbid pulmonary (chronic obstructive pulmonary disease 
(COPD) and asthma) and heart diseases (atrial fibrillation (AF), heart failure (HF), and coro-
nary heart disease (CHD)). The study aimed to contribute to the current knowledge on the 
complex puzzle of risk factors of AD. 
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2.1 MEMORY DISORDERS
2.1.1 dementia
Dementia is a syndrome causing deterioration in memory and, in addition, deficits in other cog-
nitive functions including aphasia, apraxia, agnosia or disturbances in executive functioning. 
The most disturbing symptom is sustainable and usually progressive worsening of memory 
functions. The cognitive decline must be severe enough to cause impairment in social or occupa-
tional functioning causing a decline from the persons’ previous level of functioning (American 
Psychiatric Association 1994). Dementia is a syndrome with many underlying causes, the most 
common being AD; others include vascular dementia (VaD), frontotemporal lobar degenerations 
(FTLD), dementia with Lewy bodies (DLB), Parkinson’s disease dementia (PDD), and other more 
rare etiologies (e.g. alcohol related dementia, HIV-related dementia, Creutzfeldt–Jakob disease). 
The main focus of this thesis is on dementia in general, and on AD and VaD, which will be dis-
cussed in detail, while other causes of dementia will be only briefly described.
Nowadays the most widely used diagnostic criteria for dementia are those defined in the 
American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, 
4th edition (DSM-IV) (American Psychiatric Association 1994) and the World Health 
Organization’s (WHO) International Classification of Diseases, 10th Revision (ICD-10) (World 
Health Organization 2004). There have also been other criteria in use especially in the past, 
but not all of these will define the same persons as being demented and this must be taken 
into account while reviewing dementia research (Erkinjuntti et al. 1997). The upcoming 5th 
edition of DSM (DSM-V), which is going to be published in May 2013, emphasizes the different 
ethiologies of dementia, and in the updated version dementia and other cognitive disorders 
are actually categorised as neurocognitive disorders rather than dementia. 
The most obvious risk factor for dementia is advanced age, and accordingly, the occurrence of 
dementia nearly doubles every 5 years after the age of 65 years. The estimated prevalence of total 
dementia among persons aged 65 to 69 years was 0.8 % in one European pooled study, while over 
one out of every fourth individual over 90 years has been estimated to be demented (Lobo et al. 
2000). In 2005, the overall global prevalence of dementia among persons ≥ 60 years was estimated 
to be 3.9 % (> 24 million people) according to an international expert panel (Ferri et al. 2005). The 
World Alzheimer Report 2009 by Alzheimer’s Disease International (ADI) estimated that in 2010 
a total of 35.6 million people worldwide are living with dementia (available at homepage of ADI: 
http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf). Moreover, if dementia preven-
tion efforts fail then the figures are estimated to continue increasing considerably in the next few 
decades (Wimo et al. 2003). This represents a huge social as well as economical burden to society. 
The worldwide societal costs of dementia have increased by 34 % in the few years between 2005 
and 2009 (Wimo et al. 2010). Consequently, finding effective preventive strategies for dementia 
should be one of the top priorities in public health politics worldwide. 
2.1.2 alzheimer’s disease
Alzheimer’s disease is nowadays regarded as the most important cause of dementia. It is esti-
mated to account for between 50 to 70 % of all dementia cases (Lobo et al. 2000, Fratiglioni et al. 
2000a). After Alois Alzheimer in 1906 first described the symptoms of Auguste D, a 51-year-old 
4woman with progressive cognitive impairment, focal symptoms, hallucinations, delusions, and 
psychosocial incompetence, the disease was long considered as a rarity (Maurer et al. 1997). At 
autopsy of Aguste D, there were plaques, neurofibrillary tangles, and arteriosclerotic changes 
found in her brain. It was not until the 1970’s that it was discovered that these histopathologi-
cal features are very commonly found in the brains of demented persons (Blessed et al. 1968). 
 The pathophysiology of AD is not yet completely understood. However, AD is histopatho-
logically characterized by the formation of extracellular amyloid plaques and intraneuronal 
neurofibrillary tangles (NFT) in the brain, resulting in neuronal dysfunction and cell death 
(Braak et al. 1995, Delacourte et al. 1999). The amyloid plaques are products of sequential pro-
teolytic cleaving process of the amyloid precursor protein (APP), an integral membrane protein 
found in many tissues and concentrated in the synapses of neurons. APP cleaving process can 
be carried out by 3 enzymes; the α-, β- and γ-secretases. The cleavage by β- and γ-secretase re-
sults in the formation of 38- to 43-amino-acid β-amyloid (Aβ) peptides. The longer Aβ peptides 
(Aβ42), which represent about 10% of all Aβ species in the brain, display an increased tendency 
to aggregate and accumulate as extracellular amyloid deposits in senile plaques (Vetrivel et 
al. 2006). Aβ aggregates are also found in the walls of cerebral blood vessels causing amyloid 
angiopathy. On the contrary, the nonamyloidogenic cleavage process of APP by α-secretase 
has been found to be neuroprotective. In AD, the balance of APP processing in the brain is in 
favour of the amyloidogenic pathway. Some investigators have suggested that the oligomeric 
forms of Aβ may actually be more synaptotoxic than the Aβ plaques, these in fact may serve 
as a protective mechanism against the oligomeric species (Shankar et al. 2008). The second 
histopathological hallmark of AD is the formation of intracellular NFT’s. NFT’s are the result 
of hyperphosphorylation of the microtubule associated protein, Tau, leading to its oligomeriza-
tion, and microtubule destabilization within the cell, and ultimately, to apoptosis of the neuron 
(Avila 2006). These characteristic histopathological changes can first be found in the medial 
temporal lobe structures (including entorhinal cortex and hippocampus) and subsequently 
during disease progression also the neocortex becomes widely affected, and the progression 
of the changes takes place in a very hierarchical manner (Braak et al. 1995, Delacourte et al. 
1999). As a result, there is marked neuronal loss and consequently brain atrophy seen espe-
cially in the temporal lobe structures, and later during the disease course, also cortical and 
central atrophy is evident (Cras et al. 1995). However, neither hyperphosphorylation of tau nor 
amyloid plaque formation are exclusively found in AD. There are also other neurodegenera-
tive diseases, referred as to tauopathies, which are characterised by intraneuronal filamentous 
deposits consisting of hyperphosphorylated tau (e.g. frontotemporal dementia, frontotemporal 
dementia with parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear 
palsy (PSP), and corticobasal degeneration (CBD)) (Goedert et al. 2005). There are also some 
amyloid plaques, usually called diffuse plaques, formed during normal aging in the brain, but 
histopathologically they are somewhat different from the neuritic plaques commonly seen in 
AD. Moreover, clinically diagnosed probable AD is considered to be a pathologically heterog-
enous disorder with many persons exhibiting mixed pathologies (Schneider et al. 2009). 
The current diagnosis of AD is based on the typical clinical picture and specific support-
ive findings in clinical examination. There are several guidelines for diagnosing AD, in-
cluding the DSM-IV and the ICD-10. However, the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) work group clinical criteria for the diagnosis of AD published 
in 1984 (McKhann et al. 1984) are most widely used in research. They are well validated and 
provide a sufficient diagnostic accuracy of 85 to 90 % in diagnosing probable AD (Gearing et al. 
51995). The core of the symptoms is a progressive impairment in episodic memory. According to 
the NINCDS-ADRDA criteria, the diagnosis of probable AD include 1) dementia established by 
clinical examination and documented by a standard test of cognitive functions and confirmed 
by neuropsychological tests, 2) deficits in two or more areas of cognition, 3) progressive wors-
ening of memory and other cognitive functions, 4) no disturbance of consciousness, 5) onset 
between ages 40 and 90, typically after 65, and 6) absence of other systemic or brain disorder 
that would account for the symptoms. In addition, the diagnosis is supported by a progressive 
deterioration of specific cognitive functions including aphasia, apraxia, and agnosia, impaired 
activities of daily living, family history of AD, and normal laboratory assessments. Features 
that do not support the diagnosis include a sudden onset of symptoms, focal neurological 
symptoms, seizures, and gait disturbances very early in the course of the disease. The di-
agnosis of definite AD requires that the clinical criteria for probable AD are fulfilled, and in 
addition, that there is histopathological evidence obtained on autopsy. The Neuropathology 
Task Force of the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) in 1991 
published a standardized neuropathology protocol for the postmortem assessment of demen-
tia in order to refine the diagnostic criteria of AD (Mirra et al. 1991).  
A need to revise the diagnostic criteria of AD has emerged from the better understanding of 
clinical phenotype and advances in knowledge of the biological basis of AD, and furthermore, 
the recognition of distinctive biological markers of AD. There is also a desperate need to develop 
early intervention strategies for the prevention of AD. Since it is known that the disease process 
starts to evolve in the brain years before the first clinical symptoms appear, there is an explicit 
need for a protocol which could diagnose AD as early as possible, even before the first symptoms. 
Interventions with disease-modifying therapies would be expected to be more effective, and 
more precisely targeted against the putative neuropathological mechanisms, when conducted 
earlier in the disease course. Subsequently, when extensive neuronal loss and brain atrophy 
are already present, the effect of interventions may be much more limited. Recent advances in 
neuroimaging, cerebrospinal fluid (CSF) assays, and other biomarkers now provide the ability 
to detect evidence of the AD pathophysiological process in vivo. The major AD biomarkers that 
have been widely investigated at this time may be divided into two classes based on the bio-
logical processes which they measure (McKhann et al. 2011). Biomarkers of β-amyloid protein 
deposition are low CSF levels of Aβ
42 and positive positron emission tomography (PET) amyloid 
imaging. The second category includes biomarkers of downstream neuronal degeneration or 
injury. The three major biomarkers in this category are elevated levels in CSF tau (both total tau 
and phosphorylated tau), decreased 18-fluorodeoxyglucose uptake on PET in temporo–parietal 
cortex, and disproportionate atrophy on structural magnetic resonance imaging (MRI) in medial, 
basal, and lateral temporal lobe, and medial parietal cortex. It has been hypothesized that the 
earliest detectable pathological change in the brain of an individual with AD is Aβ accumulation 
(Sperling et al. 2011). However, some investigators have proposed that synaptic, mitochondrial, 
metabolic, inflammatory, neuronal, cytoskeletal, and other age-related alterations may play an 
even earlier, or more central, role than Aβ in the pathogenesis of AD (Pimplikar et al. 2010). An 
elevated CSF tau level is not specific to AD and is thought to be a later biomarker of neuronal 
injury, accompanied by synaptic depletion and neuronal loss (Sperling et al. 2011). Later during 
the disease course, neurodegenerative changes related to AD become visually detectable as brain 
atrophy in structural MRI. However, the association between the pathological features of AD and 
clinical dementia may depend on the age; the association is believed to be stronger in younger 
old persons than in older old persons (Savva et al. 2009). Thus, age must be taken into account 
when assessing the effect of interventions against AD.                                                      
6With the accumulation of new knowledge, the diagnosis of AD is no longer merely a diagnosis 
of exclusion. A revision of the NINCDS-ADRDA criteria for establishing new research criteria 
for the diagnosis of AD was published in 2007 (Dubois et al. 2007). These criteria emphasize the 
significance of these new biomarkers for AD. In order to meet the criteria for probable AD, the 
individual must have: 1) early and significant episodic memory impairment as a core symptom 
and 2) one or more of the supportive biomarker criteria, i.e. the presence of medial temporal lobe 
atrophy in MRI, an abnormal CSF biomarker (low Aβ42, increased total tau or increased phospho-
tau concentration, or combinations of these three), a specific pattern on functional neuroimaging 
with PET, and a proven AD autosomal dominant mutation within the immediate family. In addi-
tion, the diagnosis of definite AD does not necessarily require neuropathological confirmation on 
autopsy, but can also be made in the presence of clinical evidence together with histopathological 
evidence of the disease in brain biopsy or genetic evidence (mutation in chromosome 1, 14 or 21). 
Another revision of the NINCDS-ADRDA criteria by an international workgroup convened by 
National Institute on Aging and the Alzheimer’s Association has also been published in 2011 
(McKhann et al. 2011). According to these criteria, in individuals who meet the core clinical 
criteria for probable AD dementia, the biomarker evidence may increase the certainty that the 
basis of the clinical dementia syndrome is the AD pathophysiological process. However, the AD 
biomarker tests are not proposed for routine diagnostic purposes at the present time.
Sporadic AD is by far the most common form of AD. However, there is also a particular 
class of AD, familiar AD (FAD), which needs to be discussed here. At the present, FAD has 
been linked to mutations in three genes: APP, PS-1 (presenilin-1) and PS-2 (presenilin-2) 
located in chromosomes 21, 14 and 1, respectively. However, it has been speculated that ad-
ditional susceptibility genes exist (Bertram et al. 2004). The identified genes are responsible 
for the expression of the proteins APP, PS-1 and PS-2. APP is the precursor protein of Aβ, 
and PS-1 and PS-2 are components of a protein complex that is involved in the cleavage of 
APP to form Aβ. Thus, the accumulation and aggregation of Aβ may be augmented by muta-
tions in these genes, resulting in very early Aβ formation in the brain. The clinical picture 
in FAD is the same as that encountered in sporadic AD, but the symptoms start very early, 
usually around 40 to 50 years of age. Compared to sporadic AD, FAD is rare; it accounts for 
only 5 % of all AD cases. 
2.1.3 vascular dementia
The second most common form of dementia is VaD, constituting approximately 15 to 20 % of all 
dementia cases. There are several guidelines for diagnosing VaD, including the criteria defined 
in the DSM and ICD coding systems, and Alzheimer’s Disease Diagnostic and Treatment Center 
(ADDTC) (Chui et al. 1992), and Hachinski Ischemic Scale (HIS) (Hachinski et al. 1975) crite-
ria. In 1993, the Neuroepidemiology Branch of the National Institute of Neurological Disorders 
and Stroke (NINDS) convened an International Workshop with support from the Association 
Internationale pour la Recherche et l’Enseignement en Neurosciences (AIREN) and published 
research criteria for the diagnosis of VaD (Roman et al. 1993). These guidelines emphasize: 1) 
the heterogeneity of vascular dementia syndromes and pathologic subtypes including ischemic 
and hemorrhagic strokes, cerebral hypoxic-ischemic events, and senile leukoencephalopathic 
lesions, 2) the variability in the clinical course of the disease, which may be static, remitting, 
or progressive, 3) specific clinical findings early in the disease course (e.g. gait disorder, incon-
tinence, or mood and personality changes) that support a vascular rather than a degenerative 
cause, 4) the need to establish a temporal relationship between stroke and dementia onset for a 
secure diagnosis, 5) the importance of brain imaging to support clinical findings, 6) the value of 
7neuropsychological testing to document impairments in multiple cognitive domains, and 7) the 
value of using a protocol for neuropathologic evaluations and correlative studies of clinical, ra-
diologic, and neuropsychological features. These criteria were created especially for the purpose 
of case definition in epidemiologic studies. As evaluated neuropathologically, the sensitivity of 
the criteria is estimated to be 58 % and specificity 80 % in one study of 113 autopsied elderly pa-
tients with dementia (Gold et al. 1997). Thus, in particular, the sensitivity of the criteria is rather 
low. Furthermore, the diagnostic criteria for VaD in different coding systems differ considerably 
in their abilities to identify VaD patients; in one study with a series of patients with poststroke 
dementia, the number of cases that could be classified as VaD varied between 32 to 91 % accord-
ing to the different criteria used in that study (DSM-III, ADDTC, NINDS-AIREN, ICD-10, DSM-
IV) (Pohjasvaara et al. 2000). A recent review has suggested that the NINDS-AIREN criteria are 
the most specific and useful criteria in research, but the different criteria proposed for vascular 
dementia are not interchangeable (Wiederkehr et al. 2008).
A clear differentiation of AD and VaD may be clinically difficult in some cases, especially 
when extensive ischemic white matter lesions accompany an otherwise typical clinical picture 
of AD. In fact, it is recognized that especially among elderly persons, neurodegenerative and 
vascular neuropathology often co-exist and “mixed” dementia or AD with cerebrovascular 
disease (CVD) might actually be the most common form of dementia among persons of ad-
vanced age (Kalaria 2002). “Mixed” dementia is rarely diagnosed in the clinic, however, as the 
majority of diagnostic procedures are biased toward a diagnosis of AD, and in fact, signifi-
cant CVD and stroke have generally been considered as an exclusion criteria for the clinical 
diagnosis of AD. Furthermore, the definition of dementia specifies memory impairment as an 
essential feature of the disease. This definition identifies patients with AD, but often misses 
the executive dysfunction typical of cognitive disorders due to vascular causes. Thus, the 
emphasis of VaD research has shifted towards the concept of vascular cognitive impairment 
(VCI). VCI is considered as the modern term related to vascular burden of the brain, reflecting 
all the encompassing effects of CVD on cognition. VCI includes all levels of cognitive decline 
from milder deficits up to outright dementia. In an attempt to identify and describe those in-
dividuals with cognitive impairment related to vascular factors, or VCI, in 2006 NINDS and 
Canadian Stroke Network (CSN) published their vascular cognitive impairment harmoniza-
tion standards (Hachinski et al. 2006). One important reason for developing these criteria was 
that VCI patients who are not yet demented are better candidates for participating in clinical 
trials because they are at earlier stages of their illness. Since vascular risk factors (e.g. hyperten-
sion, high cholesterol, and diabetes) are treatable, it has been postulated that early treatment 
should prevent, postpone, or mitigate VCI as well as the possible vascular exacerbation of AD. 
Furthermore, since AD and VaD or VCI also share many of the same risk factors, they both 
must be considered as a focus of future research and the knowledge on the pathophysiological 
mechanisms leading to these conditions must be further expanded.
2.1.4 other dementias
Other more rare, but clinically relevant, forms of dementia include dementia with Lewy bodies 
(DLB) (McKeith et al. 2005), Parkinson’s disease dementia (PDD) (Emre et al. 2007), and fronto-
temporal lobar degenerations (FTLD) (McKhann et al. 2001). It has been proposed that DLB is 
the second most common type of degenerative dementia in the elderly, possibly accounting for 
up to 15 to 25 % of all dementia cases in autopsy samples (McKeith et al. 1996). Clinically, DLB 
is characterized by progressive cognitive impairment, leading to dementia with fluctuating 
cognition, recurrent detailed visual hallucinations, and parkinsonism (McKeith et al. 2005). 
8Attention deficits and problems in executive functions and visuospatial performance usually 
occur early in the disease course and are prominent. The major histological feature of DLB 
is the presence of neuronal inclusion bodies called Lewy bodies in subcortical and cortical 
areas. Lewy bodies consist mainly of insoluble aggregates of α-synuclein protein associated 
with other proteins such as ubiquitin. However, there is a pronounced neuropathological and 
clinical overlap with AD as well as with PDD. In PD, Lewy bodies are found in the substantia 
nigra, and if progressing to PDD, they are usually also found widespread in the cortex (Tsuboi 
et al. 2007). In fact, DLB and PDD have been speculated to represent two clinical entities on the 
spectrum of Lewy body disease. Many patients with DLB also have AD neuropathology, i.e., 
cortical amyloid plaques and also to a lesser extent neurofibrillary tangles. Conversely, Lewy 
bodies are also frequently found in cases of AD, including patients with both sporadic AD and 
FAD (Hamilton 2000). Thus, DLB can coexist with AD. 
FTLD comprises a heterogeneous group of syndromes defined clinically by early and pro-
gressive changes in behaviour and personality and/or in language (McKhann et al. 2001). 
Memory and other cognitive functions in contrast to language are relatively well preserved 
until the late stages of the disease. These disorders are especially important in the differential 
diagnostics of early onset dementia because the symptoms usually affect individuals younger 
than 65 to 70 years. Neuropathologically, FTLD is attributable to a neurodegeneration in the 
frontal and/or temporal lobes. The histopathological findings vary considerably from tau-pos-
itive and ubiquitin-positive inclusions to those lacking any distinct histopathological features 
apart from frontotemporal neuronal loss and gliosis. 
There are still a number of other disorders which can cause dementia (e.g. dementia due to 
the neurodegenerative diseases multisystem atrophy (MSA), PSP and CBD, Huntington’s dis-
ease, Creutzfeldt–Jakob disease, HIV-related dementia and dementia due to normal pressure 
hydrocephalus), but they are very rare and will not be discussed in detail here, because the 
focus of this thesis is on dementia as a whole and specifically on AD and VaD.
2.1.5 mild cognitive impairment
A subtle cognitive decline can precede the more distinctive symptoms of AD by many years. 
This has established the need for defining the clinical entity preceding dementia. During the 
last decades, there have been many definitions of the mild changes occurring in elderly cogni-
tion, starting from the 1950’s term “benign senescent forgetfulness” introduced by the Czech-
Canadian psychiatrist and neurologist V. A. Kral (Kral 1962). During the 1980’s and 1990’s the 
terms “age-associated memory impairment” (AAMI) and “aging-associated cognitive decline” 
(AACD) (Levy 1994) were the first which contained specific clinical criteria. However, mild 
cognitive impairment (MCI) is nowadays the most frequently used term. MCI is proposed 
to be a transitional state between normal aging and dementia. However, it is known to be a 
heterogeneous state in terms of clinical presentation, etiology, and prognosis (Mariani et al. 
2007). The rate of conversion of MCI to dementia varies among studies, but is estimated to be 
approximately 4 to 11 % per year (Panza et al. 2005). It is also known that several cognitive 
functions may decline with normal aging without any underlying neurodegenerative disease 
and with no progression towards dementia, (Christensen 2001, Christensen et al. 1999) and 
moreover, some of those persons diagnosed with MCI may even revert back to normal cogni-
tive functioning. Thus, differentiating between the predromal stage of dementia and the stable 
MCI or cognitive decline related to normal aging is still a challenging task, nonetheless the 
clinical data on MCI have increased enormously during recent years and huge efforts have 
been made in better defining this clinical entity.
9The criteria of MCI proposed by the Mayo Clinic Alzheimer’s Disease Research Center 
(MCADRC) have been widely used during recent years in many studies, especially in clinical 
trials on MCI (Smith et al. 1996, Petersen et al. 1995). The criteria include: 1) memory complaint 
by patient, family, or physician, 2) normal activities of daily living, 3) normal global cognitive 
function, 4) objective impairment of memory or one other area of cognitive function as evi-
denced by scores > 1.5 standard deviation (SD) below the age-appropriate mean, 5) Clinical 
Dementia Rating (CDR) score of 0.5, and 6) absence of dementia. New consensus criteria for 
MCI have also been introduced by an international expert panel (Winblad et al. 2004). The con-
tent of these criteria is essentially the same as those previously suggested by the MCADRC, but 
these allow for minimal impairment of complex instrumental functions along with preserved 
activities of daily living. Furthermore, after establishing that an individual person has MCI, the 
clinical presentation may be classified according to three subtypes: amnestic, multiple domain 
(with or without a memory component), and single nonmemory domain (e.g. executive func-
tions, language, visuospatial skills). A similar classification has also been proposed by another 
international group of experts in order to emphasize the multiple clinical presentations and 
underlying etiologies of MCI (Petersen et al. 2001). However, a substantial body of evidence 
suggests that MCI, especially its amnestic form, largely represents predromal AD (Dubois et al. 
2004). Subjects diagnosed with MCI are estimated to convert to AD at a rate of 10 to 12 % per 
year (Petersen et al. 1999). Consequently, a diagnosis of MCI has been recognized as marking 
an individual as suitable candidate for possible therapeutic intervention.
2.2 RISK AND PROTECTIVE FACTORS
In recent years several factors have been examined in relation to the risk of dementia and AD. 
There is a growing body of evidence indicating that the development of dementia is a result 
of interaction between genetic susceptibility and environmental factors. The current evidence 
on risk or protective factors for dementia and AD has been summarized in two recent reports, 
one by the National Institutes of Health (NIH) (Williams et al. 2010) and other by the Swedish 
Council on Health Technology Assessment (SBU) (available at homepage of SBU: http://www.
sbu.se/upload/Publikationer/Content1/1/Dementia_vol1.pdf). Table 1 presents a summarized 
overview of these main putative risk or protective factors. They consist of a mixture of modi-
fiable as well as non-modifiable risk factors. As illustrated in Table 1, various lifestyle related, 
modifiable factors have been linked to the disease risk. Moderate or high evidence for the as-
sociation has been reported for apolipoprotein E (APOE) ε4 allele, familial aggregation, high 
blood pressure and high cholesterol at midlife, diabetes, low education, physical activity, and 
anti-hypertensive drugs. The evidence regarding the other factors is still regarded as less con-
vincing. The present work gives a brief overview of the main identified risk and protective 
factors. A detailed review is presented on the risk factors that are of central interest in this 
thesis, specifically: smoking, pulmonary diseases and heart diseases. 
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Table 1. The main examined risk and protective factors for dementia and AD
RISK FACTORS PROTECTIVE FACTORS
DEMENTIA
APOE ε4 allele Anti-hypertensive drugs
Familial aggregation Physical activity
High blood pressure Moderate alcohol use
Diabetes Social network
Low education Mediterranean diet
Smoking Statins
Obesity Hormone replacement therapy?
High homocysteine levels Non-steroidal anti-inflammatory drugs?
Cardiovascular disease
Cerebrovascular disease
Inflammation markers
Folate/B12-vitamin deficiency
Depression
Low socio-economic status
Head trauma
ALZHEIMER’S DISEASE
APOE ε4 allele Physical activity 
Familial aggregation Moderate alcohol use
High blood pressure Social network
High cholesterol levels Mediterranean diet
Diabetes Statins
Low education Hormone replacement therapy?
Smoking Non-steroidal anti-inflammatory drugs?
Obesity
High homocysteine levels
Cardiovascular disease
Cerebrovascular disease
Inflammation markers
Folate/B12-vitamin deficiency
Depression
Low socio-economic status
Head trauma
2.2.1 sociodemographic and socioeconomic risk factors
Age and family history were the first established risk factors for sporadic dementia and AD. 
The most obvious risk factor for dementia is advanced age. Both the incidence and prevalence 
of dementia increase in conjunction with aging; the occurrence nearly doubles every 5 years 
after the age of 65 years (Lobo et al. 2000). Those individuals who have at least one first degree 
relative with dementia are at an increased risk of developing dementia compared to persons 
without a family history, and this effect has also been shown to exist among various ethnic 
croups (van Duijn et al. 1991, Devi et al. 2000). Ethnic group may influence the overall occur-
rence of dementia; higher rates of dementia have been reported among African-American and 
Latino populations than in non-Latino Whites (Gurland et al. 1999). Gender may also affect 
the disease risk; women are known to display an increased risk especially of developing AD 
compared to men (Fratiglioni et al. 2000a, Launer et al. 1999). A higher risk of dementia and 
AD has also been linked with low educational level (Launer et al. 1999, Ott et al. 1995, Anttila 
et al. 2002). Lower socio-economic status may also predict the risk of developing AD (Evans 
et al. 1997).
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2.2.2 Modifiable risk factors
Many lifestyle related and environmental factors have recently been linked to the risk of 
dementia and AD. These have evoked a great deal of interest, as many of these factors are 
easily modifiable. Obesity is usually caused by poor nutrition and low physical activity, and 
it is nowadays one of the major public health problems in the Western countries. It consti-
tutes a major risk factor for vascular diseases, and is also one of the most important actual 
causes of death in the United States (Mokdad et al. 2004). Obesity especially in midlife has 
been linked to an increased risk of dementia and AD in several studies (Kivipelto et al. 2005, 
Whitmer et al. 2005, Kalmijn et al. 2000). A diet rich in saturated fats may increase the risk 
of dementia and AD irrespective of the BMI value, whereas moderate intake of unsaturated 
fats may be protective (Laitinen et al. 2006, Morris et al. 2003). Moderate alcohol drinking 
has also been shown to be protective of dementia while frequent alcohol drinking may pre-
dispose to the disease (Anttila et al. 2004, Ruitenberg et al. 2002). Regular physical activity 
(Rovio et al. 2005, Laurin et al. 2001) as well as a rich social network (Fratiglioni et al. 2000b), 
being married (Hakansson et al. 2009, Helmer et al. 1999), and social and mental activities 
(Wang et al. 2002) have all been associated with a reduction on the risk of dementia and AD. 
Many established risk factors for vascular diseases have also been linked to an increased 
risk of dementia and AD. Hypertension is a well-recognised risk factor for stroke and coro-
nary heart disease (CHD). Recently, several population-based studies have demonstrated 
that elevated blood pressure in midlife can also increase the risk of dementia and AD in 
late-life (Whitmer et al. 2005, Kivipelto et al. 2001, Launer et al. 2000). However, interestingly, 
a decline in blood pressure is seen in the years preceding the diagnosis of dementia (Skoog 
et al. 1996, Qiu et al. 2004). This low blood pressure has actually been speculated as being 
an accelerating factor in the neurodegenerative process in the brain after the appearance 
of neurodegenerative lesions in strategic cerebral locations regulating blood pressure have 
first initiated the decline. Indeed, a lower blood pressure has been detected in the demented 
individuals than in their non-demented counterparts (Guo et al. 1996). A similar association 
has been detected between serum cholesterol values and dementia risk; i.e. high cholesterol 
in midlife has been shown to increase the risk of dementia and AD (Whitmer et al. 2005, 
Kivipelto et al. 2001, Notkola et al. 1998), but a decline in cholesterol after midlife is observed 
in those individuals who will develop dementia in late-life (Notkola et al. 1998, Solomon et 
al. 2007). It has been speculated that the reduction in the cholesterol level may reflect the 
ongoing neurodegenerative disease process in the brain, and it may even represent a risk 
marker for late-life cognitive impairment. However, the relationships between these factors 
are complex and may also at least partly reflect phenomena related to physiological aging 
and also changes in lifestyle (such as diet, physical activity, or smoking). There is also evi-
dence that diabetes mellitus may contribute to the development of dementia and AD (Ott et 
al. 1999, Peila et al. 2002, Xu et al. 2004). There are many mechanisms through which diabetes 
has been postulated to influence the risk of dementia, including the toxic impact of hyper-
glycemia, the appearance of insulin resistance, the presence of oxidative stress, advanced 
glycation endproducts, inflammatory cytokines, and vascular mechanisms. Interestingly, 
individuals with diabetes have been shown to display more vascular lesions and less AD-
related neuropathology in the brain in post-mortem autopsy, and it may be that fewer neu-
ropathologic lesions are needed to evoke dementia in these persons with cerebrovascular 
lesions (Ahtiluoto et al. 2010). Furthermore, these vascular risk factors often occur simultane-
ously (defined as the metabolic syndrome), and the clustering of these vascular risk factors 
has been shown to additively increase the risk of dementia (Whitmer et al. 2005, Kivipelto 
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et al. 2001, Luchsinger et al. 2005). Subsequently, the question has risen if anti-hypertensive 
drugs, statin treatment for hypercholesterolemia, and diabetes medication can decrease the 
risk of developing dementia and AD. There is some evidence that antihypertensive treatment 
(Poon 2008) and statins (Pac-Soo et al. 2011) may be beneficial in preventing dementia, but the 
results have been far from consistent. However, the present understanding that vascular fac-
tors seem to have an impact on the disease process already starting from midlife stresses the 
importance of long-term treatment of these risk factors already starting at least from midlife. 
Likewise, further research is needed on the association of these factors with dementia and 
the treatment of the risk factors starting already from midlife to obtain the ultimate answers 
about the role of these factors in the development of the disease.
2.2.3 The apolipoprotein E ε4 allele
Thus far APOE ε4 allele is the only established susceptibility gene for sporadic or late-onset 
AD. It has been estimated that it accounts for about 60 % of the genetic component of late-
onset AD (Rubinsztein et al. 1999). The APOE gene located in chromosome 19 has 3 common 
alleles: ε2, ε3, and ε4, corresponding to 6 different phenotypes. In typical Caucasian popula-
tions, the most common allele is ε3 with ε2 being the most infrequent; the average frequen-
cies of ε2, ε3 and ε4 are 8 %, 75 % and 15 %, respectively (Davignon et al. 1988). Moreover, 
some variations in the frequency of the alleles have been reported in different populations 
(Corbo et al. 1999). In Finland and Scandinavia, the proportion of APOE ε4 carriers in the 
population is known to be somewhat greater than in some other European countries (on 
average 15 %) (Schiele et al. 2000, Ehnholm et al. 1986). In the Finnish Cardiovascular Risk 
Factors, Aging and Dementia (CAIDE) study, more than 30 % of the study population were 
found to carry at least one ε4 allele, thus, the occurrence of the ε4 allele in that study can 
be considered as high. There is also evidence that the effect of the ε4 may vary in different 
ethnic groups; ε4 may be weaker risk factor for AD among African Americans and Hispanics 
than in Caucasians and Japanese (Farrer et al. 1997). In addition to AD, the APOE ε4 carriers 
have an increased risk of several diseases including cardiovascular disease, cerebrovascular 
disease, and neurodegenerative disorders including LBD (Smith 2000). The ε4 allele has also 
been linked to increased mortality (Ewbank 2004); however, results concerning the effect of 
APOE ε4 on survival are contradictory. In one population-based study,the APOE phenotype 
or AD did not influence mortality in the aged population (Koivisto et al. 2000). Once AD had 
become manifest, APOE ε4 alone did not influence survival. However, in subjects with AD 
not carrying APOE ε4, men had reduced survival compared to women.
APOE carries out multiple functions in the brain and different alleles have specific proper-
ties. The protein produced by the APOE gene is an important component of many types of 
plasma lipoproteins within many organs and cell types in the human body, and it is crucial 
in lipid transport. It influences lipoprotein metabolism through its action as a receptor ligand 
that mediates the uptake of lipoprotein particles into cells, and its major function is to redis-
tribute lipids and participate in cholesterol homeostasis (Beffert et al. 1998, Weisgraber et al. 
1996). The liver is the largest producer of the protein while the brain is the second largest. 
In the central nervous system APOE is mainly synthesised and secreted by astrocytes and 
microglia, but it can also be produced in neurons (Beffert et al. 1998). It is synthesized also 
by macrophages and monocytes. APOE is involved in the mobilization and redistribution of 
cholesterol during neuronal growth and after injury, but is crucial in many other functions 
such as nerve regeneration, immunoregulation and also in the activation of several lipolytic 
enzymes (Mahley et al. 2000). The exact mechanisms by which APOE influences AD are un-
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known, but the ε4 allele has been shown to intensify all the biochemical disturbances char-
acteristics of AD, including Aβ deposition, tangle formation, neuronal cell death, oxidative 
stress, synaptic plasticity and dysfunctions of lipid homeostasis and cholinergic signalling 
(Cedazo-Minguez et al. 2001). 
The first results indicating that APOE ε4 carriers have an increased risk of late-onset 
AD compared to the non-carriers were published in 1993 (Corder et al. 1993). Furthermore, 
the age at the onset of AD is known to be lower among the ε4 carriers as compared to the 
non-carriers (Corder et al. 1993). In contrast, the ε2 allele may be protective of AD, since it is 
underrepresented in persons with AD (Corder et al. 1994). However, at least one third of the 
persons with AD lack ε4 and as many as 50 % of people who do have ε4 survive at least to 
age 80 years without developing AD (Myers et al. 1996). Indeed, it has been speculated that 
the risk of developing AD is further modified by many other factors including several envi-
ronmental and lifestyle related factors, and that the risk attributable to these factors may be 
further modified according to the APOE genotype. For example, the effects of smoking (Ott et 
al. 1998, Merchant et al. 1999, Lindsay et al. 2002, Tyas et al. 2003, Aggarwal et al. 2006, Reitz et 
al. 2007, Ronnemaa et al. 2011), physical activity (Rovio et al. 2005, Lindsay et al. 2002), alcohol 
drinking (Anttila et al. 2004, Lindsay et al. 2002), diet (Laitinen et al. 2006, Barberger-Gateau 
et al. 2007), and marital status (Hakansson et al. 2009) on the risk of dementia an AD have 
been postulated to vary according to the APOE ε4 carrier status. It seems that the ε4 allele 
mainly magnifies the lifestyle risks for dementia, but the results have not been consistent. It 
has also been suggested that the effect of the ε4 allele on the risk of AD may attenuate with 
increasing age in such a way that the effect diminishes after the age of 70 years (Farrer et al. 
1997). However, the previous studies considering the possible modifying effect of APOE on 
the risk of dementia and AD have been mainly carried out among elderly cohorts with rather 
short follow-up times and only a few studies have investigated these gene-environmental 
interactions in midlife cohorts. Taken together, the long preclinical phase of AD during 
which the disease process evolves in the brain and the attenuating effect of APOE during 
aging clearly warrants further research about the gene-environmental interactions in the 
development of AD in various age groups and populations.
2.2.4 smoking
The World Health Organization estimates that there are over one billion cigarette smokers in 
the world. Although smoking has declined in the developed countries, tobacco consumption 
is increasing in some developing countries. Smoking is an established risk factor for several 
diseases including cancer, CHD, and many pulmonary diseases, especially COPD (Bartecchi 
et al. 1994). However, the association of smoking with dementia and especially with AD has 
been controversial. Several early case-control studies suggested an inverse relation between 
smoking and dementia (Graves et al. 1991, Lee 1994, Van Duijn et al. 1994). Later these find-
ings have been explained to result from selective survival; i.e. increased mortality related 
to smoking being even more pronounced among demented smokers (Wang et al. 1999), and 
consequently, long-term smokers are found out to be underrepresented among the elderly 
population when examining in a cross-sectional study (Riggs 1993). More recently also sev-
eral prospective studies have investigated the association between smoking and dementia/
AD and have yielded conflicting results. They are listed in Table 2. The first prospective 
study was published in 1992, and reported no association between smoking and AD in a 
small community-based cohort with a follow-up of 4 years (Hebert et al. 1992). There are also 
other studies which claim that smoking may be unrelated to dementia and AD (Yoshitake et 
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al. 1995, Broe et al. 1998, Brayne et al. 1998, Wang et al. 1999, Doll et al. 2000, Lindsay et al. 
2002, Peters et al. 2009a). On the other hand, other studies have reported that smoking does 
increase the risk of developing dementia, AD or VaD (Ott et al. 1998, Launer et al. 1999, 
Merchant et al. 1999, Tyas et al. 2003, Moffat et al. 2004, Juan et al. 2004, Luchsinger et al. 
2005, Aggarwal et al. 2006, Reitz et al. 2007, Chen et al. 2011, Ronnemaa et al. 2011, Kimm et 
al. 2011). However, most of these studies were conducted in elderly cohorts with relatively 
short follow-up times (2 to 7 years). Thus far, only 3 previous studies have investigated smok-
ing specifically in midlife in relation to late-life dementia (Tyas et al. 2003, Ronnemaa et al. 
2011, Kimm et al. 2011). Findings from the Honolulu-Asia Aging Study (HAAS) indicated an 
increased risk of dementia, AD and VaD among midlife smokers during a follow-up time of 
25 to 30 years; however, this study was conducted only among Japanese-American men (Tyas 
et al. 2003). The study reported also neuropathological data of 218 autopsied cases, indicat-
ing that the number of neuritic plaques increased with the amount of cigarettes smoked. 
Another study from Sweden, which was also conducted among men only, has reported that 
midlife smoking increased the risk of dementia and VaD but not AD after a follow-up of 29 
years (Ronnemaa et al. 2011). Additionally, this study had another baseline at late-life (with 
a mean age of approximately 71 years), and in these analyses, there was no association be-
tween smoking and all types of dementia among all the participants when there was a 13 
years follow-up. However, a tendency towards an increased risk of dementia was observed 
among the APOE ε4 non-carriers who smoke in late-life, but no risk increase was seen among 
the smoking APOE ε4 carriers. Yet another study with a very large cohort of 848 505 mid-
dle-aged individuals from Korea reported an increase in the risk of all dementia subtypes 
(dementia, AD, and VaD) among women who smoke but not among men (Kimm et al. 2011). 
However, when the analyses were carried out according to age group (< 65 and ≥ 65 years) 
smoking was found out to increase the risk of AD also in men younger than 65 years of age. 
With respect to women, in these analyses smoking was not found to be a significant risk 
factor of dementia in women aged less than 65 years, but an increased risk of AD related to 
smoking was observed in women of 65 years or older. There is still one small cohort study 
with a fairly long follow-up time of 19 years which has pointed to an increased risk of AD 
among ever-smokers; however, the participants were all men and since the baseline age of 
the participants was 66 years, it was beyond middle-age (Moffat et al. 2004). 
Another limitation of the earlier studies is that the APOE ε4 carrier status of the partici-
pants has been evaluated in only a few of the studies. The studies that have taken the APOE 
ε4 carrier status into account indicate that this may be relevant in respect of modulating 
the risk of dementia among smokers. Indeed, in some of these studies, the increased risk of 
dementia related to smoking could be seen only among the APOE ε4 non-carriers (Ott et al. 
1998, Aggarwal et al. 2006, Reitz et al. 2007, Ronnemaa et al. 2011), in one study the APOE 
status did not modify the risk of AD among smokers when measured by the smoking level 
(Tyas et al. 2003), and in one study the smoking APOE ε4 non-carriers were found out to have 
only a slightly more elevated risk of AD than the smoking APOE ε4 carriers (Merchant et al. 
1999). Altogether, these reports suggest that the APOE ε4 non-carriers may be more prone 
than the APOE ε4 carriers to the deleterious effects of smoking with regard to the risk of 
dementia. However, previously published results from the present CAIDE study population 
indicate that smoking (ever vs. never) in middle age, as one of the studied lifestyle related 
factors (i.e. frequent alcohol drinking, physical inactivity, and high intake of saturated fatty 
acids and low intake of polyunsaturated fatty acids), increased the risk of dementia specifi-
cally among the APOE ε4 carriers, as compared to the non-smoking APOE ε4 non-carriers 
19
(Kivipelto et al. 2008). Furthermore, a history of heavy smoking (≥ 1 packs per day) has 
been shown to lower the onset age of AD among the APOE ε4 carriers by 5 years when they 
were compared to non-smoking APOE ε4 non-carriers (Harwood et al. 2010). Thus, the role 
of APOE ε4 carrier status in modulation of dementia risk among smokers is still not clear. 
Nonetheless, these results suggest that the association between smoking and dementia/AD 
may be complex and vary according to genotype, and these connections deserve further 
investigation.
Only a few previous studies have considered the effect of the total accumulated smoking 
exposure estimated as pack-years (the average number of cigarettes daily smoked divided 
by 20 and multiplied by the number of years of smoking) of smoking on the risk of dementia 
and AD. Results from the Rotterdam Study indicated that the risk of dementia and AD was 
greater among persons who have smoked over 20 pack-years compared to the persons who 
have smoked less (Ott et al. 1998, Reitz et al. 2007). Furthermore, two studies have claimed 
that the risk of dementia and AD among smokers increased until the level of heavy smoking 
(40 to 55 pack-years), but attenuated after that, probably due to a hardy survivor effect among 
the very heavy smokers (55 to 156 pack-years) (Tyas et al. 2003, Juan et al. 2004). Finally, one 
study could detect no association between pack-years and the risk of AD among current 
smokers, but an inverse relationship was seen among former smokers (Aggarwal et al. 2006).
2.2.5 pulmonary diseases
Chronic obstructive pulmonary disease (COPD) is a chronic pulmonary disease with progres-
sive pulmonary dysfunction and in time, consequently, hypoxemia and hypercapnia. It is a 
major cause of death and disability worldwide (Calverley et al. 2003). There are several previ-
ous studies indicating that persons diagnosed with COPD, with (Grant et al. 1982, Incalzi et al. 
1993, Ozge et al. 2006, Klein et al. 2010, Thakur et al. 2010) or without hypoxemia (Liesker et al. 
2004), exhibit cognitive impairment as reflected in the deterioration of performance in various 
cognitive tests. However, these studies have varied markedly in terms of control groups, pa-
tient groups, test batteries and are cross-sectional in nature. Furthermore, mainly unadjusted 
analyses have been reported. One cross-sectional study which described results from a cohort 
of 1202 patients with COPD and 302 referent controls indicated that even after controlling for 
age, sex, race, education, and smoking, COPD was associated with more than double the risk of 
cognitive impairment in comparison to controls (Thakur et al. 2010). There are also some pro-
spective studies that have examined the effect of pulmonary function on cognitive functioning 
and dementia. Although these studies do not address clinically diagnosed COPD but instead 
evaluate the effect of pulmonary function on cognitive functioning, low forced expiratory vol-
ume in 1 second (FEV1) in spirometry has become the defining feature of COPD and the basis 
for classification of disease severity, and thus a low FEV1 value can be a marker of COPD (Wise 
et al. 2006). Two early studies on elderly persons reported that baseline pulmonary function 
predicted cognitive change over time. The first was carried out in a cohort of 1192 community-
dwelling persons aged 70 to 79 years and it revealed that lower baseline pulmonary function 
(as measured by peak expiratory flow (PEF) rate) predicted a greater decline in performance in 
cognitive tests after a 2 to 2.5 year period (Albert et al. 1995). The other study, carried out among 
222 Swedish twin pairs (mean age 62 years), extended these findings by demonstrating the 
utility of pulmonary function (as measured by FEV1) as a predictor of cognitive performance 
over a 6-year longitudinal interval (Emery et al. 1998). A report from the Honolulu Heart Study 
was the first to assess midlife pulmonary function in relation to late-life cognitive function-
ing (Chyou et al. 1996). That study investigated the association between FEV1 measured in 
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middle age (mean age 52.5 years) and cognitive function at least 23 years later among a cohort 
of 3036 Japanese-American men in Hawaii. The cognitive function of the subjects was as-
sessed by the Cognitive Abilities Screening Instrument (CASI) (Teng et al. 1994) test at late-life. 
Compared with men who had normal or greater than normal pulmonary function, those who 
had the poorest FEV1 (< 2.5 liters) at midlife had a significantly lower CASI score at late-life. 
Furthermore, subjects less than 55 years of age at the baseline examination showed a stronger 
association between baseline FEV1 and CASI than the men aged 55 or older. Subsequently, a 
population-based study among 1291 Swedish women with a follow-up of 20 years showed that 
better pulmonary functioning (as measured in PEF, FEV1 and forced vital capacity (FVC)) in 
midlife (mean age 52 or 58 years at baseline) was associated with a lower risk of developing 
dementia and AD (Guo et al. 2007). A subgroup of these women (N=379) was also studied in 
order to examine midlife and late-life pulmonary function in relation to small-vessel disease 
as assessed by brain computer tomography (CT) (Guo et al. 2006). In this study, lower midlife 
pulmonary function was related to white matter lesions and lacunar infarcts after a follow-up 
of 26 years indicative of an increased risk of small-vessel disease in late-life. The results of the 
Berlin Aging Study (n=437, 70+ years of age) showed that decreased pulmonary function (as 
indicated by impaired ventilatory capacity in spirometry) could increase the risk of clinically 
diagnosed dementia; however, that study was cross-sectional in nature (Schaub et al. 2000). 
There is still one large population-based study (N=10975) that reported an association be-
tween reduced pulmonary function (as measured in FVC and FEV1) and poorer performance 
in cognitive assessments at baseline and with an increased risk of dementia hospitalization 
during the follow-up (mean follow-up 14 years) (Pathan et al. 2011). But, no association was 
found between pulmonary function and cognitive decline over time. In conclusion, the focus 
of previous research has mainly been on the effect of COPD on various cognitive test results 
rather than on the actual risk of clinically diagnosed MCI or dementia. While a few studies 
have described an association between pulmonary function and dementia, there are no pub-
lished studies that have investigated the long-term effects of diagnosed COPD on the risk of 
clinically diagnosed MCI and dementia in late-life.
Similarly, very little research has been conducted on long-term effects of asthma on cog-
nitive functioning or on the risk of dementia. A Swedish study with a follow-up time of 22 
years examining twin pairs did not find any association between asthma and dementia 
risk, although, atopy was associated with an increased risk of dementia and AD (Eriksson 
et al. 2008). However, a history of asthma was linked with shorter life expectancy after AD 
diagnosis in comparison to those individuals without an asthma history. In another cross-
sectional study, asthma was not associated with dementia (Ng et al. 2007). Furthermore, one 
cross-sectional study revealed that subjects who had received treatment for asthma/chronic 
bronchitis during the last 12 months had slightly lower Mini Mental State Examination 
(MMSE) scores than their counterparts without these diseases (Jelicic et al. 1997). Since this 
issue has not been examined in detail, there is a distinct gap in our knowledge of putative 
associations between asthma and the long-term risk of MCI and dementia. 
2.2.6 heart diseases
Coronary heart disease (CHD) is one of the leading causes of death and disability in the 
world (Lopez et al. 2006). Atrial fibrillation (AF) (Go et al. 2001) and heart failure (HF) (Kannel 
2000) are also common heart diseases among the elderly. These illnesses share many mutual 
risk factors with AD e.g. many cardiovascular risk factors are known to increase the risk of 
dementia and AD (Kivipelto et al. 2001, Luchsinger et al. 2005).
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The discovery of AD neuropathology (amyloid plaques) in a large proportion of non-dement-
ed coronary artery disease cases at post-mortem autopsy raised a question of whether CHD 
could predispose to AD (Sparks et al. 1990). Later this finding was also confirmed in other 
studies (Soneira et al. 1996), especially among APOE ε4 carriers with CHD (Beeri et al. 2006). 
Atherosclerosis in cerebral vessels is also known to be associated with the occurrence of neu-
ritic amyloid plaques in the brain, independently from cerebral infarcts (Honig et al. 2005). 
However, in one study there was no association detected between intracranial nor systemic 
atherosclerosis and AD neuropathology, although an increased risk of dementia was observed 
in those patients with intracranial atherosclerosis, again independently from the presence of 
brain infarction (Dolan et al. 2010). These interesting results can be considered as pointing to an 
association between CHD/atherosclerosis and dementia/AD. However, the possible association 
between CHD and dementia has subsequently been investigated only in a few cohort studies 
with elderly subjects and the results have been inconsistent. These are shown in Table 3. An 
early study carried out in the 1980s reported an increase in dementia incidence among women 
with a history of myocardial infarction (MI) (Aronson et al. 1990). Later, a small cohort study 
with both sexes linked a history of MI to the risk of dementia, but not to the risk of AD (Brayne 
et al. 1998). At the same time, a study investigating a prospective cohort of Japanese American 
men indicated that MI and angina pectoris (AP) would be risk factors for VaD (Ross et al. 1999). 
With regard to the risk of AD, early cross-sectional results from the Rotterdam study revealed 
that markers of generalized atherosclerosis (presence of atherosclerosis in the carotid arteries 
(wall thickness and plaques in ultrasonography) and of the large vessels of the legs (as assessed 
by the ankle-brachial index < 0.90)) existed in association not only with unspecified dementia 
and VaD but also with AD, and that the association was particularly clear among the APOE 
ε4 carriers (Hofman et al. 1997). There are also two prospective studies with a mean follow-up 
time of approximately 5 years which link the risk of CHD specifically to AD (Luchsinger et 
al. 2005, Newman et al. 2005). However, the study by Luchsinger et al. had a wide definition 
of heart disease including history of AF and other arrhythmias, MI, congestive heart failure 
(CHF) and AP, so, that study did not address CHD alone (Luchsinger et al. 2005). There has also 
been considerable variability in the definition of CHD in the other studies; however, almost all 
have viewed MI as a marker of CHD. In addition, AP and peripheral artery disease (PAD) have 
been regarded as markers of CHD/atherosclerosis. In fact, in the study published by Newman 
et al. the risk of dementia and AD was highest in individuals with PAD, however, a borderline 
significant increase in the risk was also observed for MI and AP (Newman et al. 2005). Finally, 
one recent Chinese study associated the history of AP with increased risk of dementia during 
a 7 year follow-up time (Chen et al. 2011).  In contrast to these reports, one prospective study 
with a mean follow-up time of 3 years did not report any relationship between a history of 
MI and dementia, AD or VaD (Hayden et al. 2006). There are also studies investigating the 
association between CHD and cognitive functioning as assessed through different cognitive 
tests. CHD predisposed to later poor cognitive functioning as measured with a cognitive test 
battery consisting of 5 standard tests in one middle aged cohort with a median follow-up time 
of 11 years (Singh-Manoux et al. 2003). This seems to be the only study which would have 
investigated this association among a middle-aged (mean age 56 years when tested for cogni-
tive function) cohort. There are also case-control studies which have not found any association 
between CHD and cognitive functioning (Grubb et al. 2000, Bursi et al. 2006). One study that 
addressed the role of CHD in clinically diagnosed MCI stated out that CHD was associated 
with MCI (Hai et al. 2011), and another study found an association to non-amnestic MCI but 
not to amnestic MCI (Roberts et al. 2010) in a cross-sectional setting. 
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AF is the most common heart rhythm disorder in elderly subjects, usually involving rapid 
heart rate and desynchronized electric and mechanical activity in the atria. Its prevalence 
increases with age and it affects up to 9 % of the population by the age of 80 (Go et al. 2001). 
It is a significant risk factor for cardiovascular morbidity and mortality. Already in the 1990s, 
cross-sectional findings from the Rotterdam Study detected a positive association between AF 
and dementia as well as AD with or without cerebrovascular disease (Ott et al. 1997). However, 
another 1990s study with a prospective cohort and a follow-up time of approximately 6 years 
observed no increase in the risk of all-cause or multi-infarct dementia among persons with AF 
(Frishman et al. 1996). It took several years before other prospective studies were published 
examining this issue. Table 4 shows the prospective studies investigating the association be-
tween AF and dementia/AD. The results are somewhat conflicting. One prospective cohort 
study, with a median follow-up time of 4.6 years, claimed that the development of dementia 
was common after the diagnosis of a first AF; the cumulative event rate in this study was 10.5 
% at 5 years (Miyasaka et al. 2007). In addition, one large study based on over 37 000 patients 
on a healthcare system database stated that AF was associated with dementia, AD, and VaD 
after a mean follow-up of 5 years (Bunch et al. 2010). One limitation of this study was that the 
dementia diagnoses were based on register data. However, the cohort is the youngest of all 
the prospective studies examining this topic; the mean age of the participants was 60.6 years. 
Interestingly, the highest risk of dementia in this study cohort was observed in the younger 
group (< 70 years) of subjects. The mean age in the other prospective studies approached 80 
years. In addition to these positive findings, there are two prospective studies, with follow-
up times of 3.5 and 4 years, in which AF was not associated with dementia or AD (Rastas et 
al. 2007, Marengoni et al. 2011). In the Vantaa 85+ study, the mean age of the participants was 
as high as 88 years and the majority (80 %) were females (Rastas et al. 2007). The other study 
consisted of results from the Kungsholmen Project, and subjects were an average 78 years old 
(Marengoni et al. 2011). There is still one randomized, double-blind, placebo-controlled multi-
center trial called the Hypertension in the Very Elderly Trial (HYVET), with a mean follow-up 
time of 2 years, which reported no association between hypertensive AF patients and dementia 
(Peters et al. 2009b). This study was also carried among an elderly 80+ years cohort. There are 
also some prospective studies which have investigated the link between AF and cognitive 
decline. One study did not find any association between AF and cognitive decline (Park et 
al. 2007), but another study observed that AF predicted a cognitive decline within the 5 year 
follow-up (Tilvis et al. 2004). Furthermore, AF was shown to be associated with the progres-
sion of MCI to dementia (Forti et al. 2007) and with faster AD progression (Mielke et al. 2007). 
There are also several works investigating this issue concentrating on patients suffering from 
stroke. AF is known to be a strong risk factor for stroke (Wolf et al. 1991) and stroke is known 
to increase the risk of dementia (Mackowiak-Cordoliani et al. 2005). Several studies have indi-
cated that AF further increased the risk of poststroke dementia from 3 months up to 2 years 
after stroke (Tatemichi et al. 1990, Censori et al. 1996, Inzitari et al. 1998, Barba et al. 2000, Altieri 
et al. 2004, Zhou et al. 2004).
HF is a condition in which the heart cannot adequately pump enough blood to meet the 
body’s needs. It is a frequent complication of most diseases of the heart, and its prevalence in-
creases exponentially from the age of 60 years (Kannel 2000). There are early reports of cog-
nitive impairment in subjects with HF primarily emerging from small case-control studies. 
A pooled analysis of some of these studies has indicated that CHF is associated with a pat-
tern of generalized cognitive impairment including memory and attention deficits (Almeida 
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et al. 2001). In addition, one prospective cohort study with a general 75+ population found 
an increased risk of cognitive decline during the 5 year follow-up among persons with HF 
(Tilvis et al. 2004). However, in the HYVET trial, HF was not related to the risk of cognitive 
decline among hypertensive patients (Peters et al. 2009b). The subsequent risk of dementia 
could not be estimated since there were too few cases with HF and dementia in the study. 
Thus so far only one study has examined the effect of HF on the risk of clinically diagnosed 
dementia in a prospective cohort study setting; it found an increased risk of both dementia 
and AD related to HF (Qiu et al. 2006). Furthermore, in that study, HF together with low 
diastolic blood pressure (< 70 mmHg) had an additive effect on the dementia risk. Another 
study from Italy also indicated that low systolic blood pressure (< 130 mmHg) predicted 
cognitive impairment among persons with HF (Zuccala et al. 2001).
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3 Aims of the Study
The general aim of the study was to investigate long-term effects of midlife smoking and 
common pulmonary and heart diseases in midlife and late-life and the subsequent risk of 
dementia/AD and cognitive impairment. Special attention was paid to potential interactions 
between environmental and genetic risk factors. The effect of midlife smoking on the risk of 
later dementia was assessed in two large cohort studies with a follow-up time of over 20 years, 
one carried out in Finland and the other in the United States. The studies regarding pulmonary 
and heart diseases were performed in the Finnish cohort including data from two late-life 
re-examinations of the cohort after the baseline visit in midlife and subsequently during the 
follow-up time of over 25 years. This made it possible to assess these risk factors both in midlife 
and in late-life and accordingly evaluate the long-term effects of these comorbid diseases on the 
dementia risk at different time points. The specific aims of the present set of the studies were:
1)  To study the impact of midlife smoking on the development of dementia and AD later 
in life taking into account also the possible modifying effect of APOE ε4 carrier status 
in a Finnish population (Study I).
2)  To study the role of midlife smoking on the development of dementia, AD, and VaD 
later in life in a multiethnic American population (Study II).
3)  To investigate the effect of common pulmonary diseases COPD and asthma in midlife 
and in late-life on the subsequent risk of cognitive impairment later in life in a Finnish 
population (Study III).
4)  To evaluate the role of common heart diseases, i.e. atrial fibrillation, heart failure, and 
coronary heart disease in midlife and in late-life on the subsequent risk of dementia 
and AD later in life in a Finnish population (Study IV).
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4 Subjects and Methods
4.1 CAIDE
Three studies (studies I, III and IV) in the present thesis are based on the Cardiovascular Risk 
Factors, Aging and Dementia (CAIDE) study carried out in eastern Finland. CAIDE is a large, 
population-based study focusing on the effects of cardiovascular and lifestyle related risk 
factors on dementia and cognitive functioning. Participants in this study were derived from 
four independent, randomly selected, population-based samples originally studied within 
the framework of the North Karelia Project and the Finnish part of Monitoring Trend and 
Determinants in Cardiovascular Disease (FINMONICA) study in 1972, 1977, 1982 and 1987 
(Puska et al. 1979, Puska et al. 1983, Vartiainen et al. 1994). These surveys were carried out to 
assess the risk factors, morbidity, and mortality attributable to cardiovascular diseases in two 
eastern provinces of Finland; North Karelia and Kuopio. In 1972 and 1977, a random sample of 
6.6 % of the population born in 1913-1947 and living in North Karelia and Kuopio provinces 
was drawn. In 1982 and 1987, the sample included the age group 25-64 years and was stratified 
so that in both areas at least 250 subjects were chosen of each sex and in each 10-year age group. 
This procedure was used to comply with the international WHO MONICA project protocol 
(WHO MONICA Project Principal Investigators 1988). The participation rates in these baseline 
surveys were high, ranging from 77 % to 96 % (Vartiainen et al. 1994). 
A random sample of 2000 survivors was invited to participate in the first re-examination 
of the CAIDE study in 1998 (Kivipelto et al. 2001). Altogether 1449 (72.5 %) individuals aged 
65 to 79 years at the end of 1997, and living in two geographically defined areas in or near the 
towns of Kuopio and Joensuu agreed to participate. However, 40 persons who were screened at 
the first phase of the re-examination, and referred for further evaluation in the second phase, 
refused to continue in the study, leaving a total of 1409 participants with complete cognitive 
assessment. A second re-examination of the CAIDE study took place during 2005-2008 when 
all the 1426 persons of the original 2000 who were still alive and living in the geographical 
area were invited to participate. 909 (63.7 %) persons agreed to participate, and for 852 there is 
a complete cognitive assessment. During both re-examinations, the survey methods followed 
those applied in the midlife surveys in all respects, and additionally the cognitive status of the 
participants was evaluated. Figure 1 presents the formation of the CAIDE study population. 
The CAIDE study was approved by the Ethics Committee of Kuopio University Hospital, and 
the participants provided written informed consent before enrolment in the study. 
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Figure 1. Formation of the CAIDE study population
4.1.1 midlife examination
The survey methods used in the baseline (midlife) visits were carefully standardized to com-
ply with international recommendations. They followed the WHO MONICA protocols in 1982 
and 1987 (WHO MONICA Project Principal Investigators 1988), and the methods used in 1972 
and 1977 were comparable with these protocols (Vartiainen et al. 1994). Briefly, the baseline 
surveys included a self-administered questionnaire on health behaviour, health status, and 
medical history of the participants. The questionnaire was sent to the participants prior to the 
examination, and a study nurse specifically trained for the survey checked the questionnaires 
during the visit to ensure that they were fully completed. Participants’ systolic (SBP) and di-
astolic blood pressure (DBP) values were measured from the right arm after a rest period of 
five minutes in a seated position. Their height, and weight were measured, and body mass 
index (BMI) was calculated as weight in kilograms divided by the square of height in meters. 
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A venous blood sample was taken to allow determination of the serum cholesterol level. All 
cholesterol assays were made in the same central laboratory and the laboratory data were 
standardized against national and international reference laboratories.   
4.1.2 first re-examination
The methods used in the first re-examination of the CAIDE study in 1998 followed those ap-
plied in the baseline surveys in all respects. Additionally the cognitive status of the participants 
was assessed as described later. Questions related to drug use as well as a questionnaire re-
lated to psychosocial factors were added. Furthermore, the APOE genotypes of the participants 
were determined from blood leukocytes by use of PCR and HhaI digestion as described by 
Tsukamoto and colleagues (Tsukamoto et al. 1993) with some minor modifications (Helisalmi 
et al. 2000). The subjects were categorized according to their APOE ε4 allele carrier status: the 
carriers were those with at least one APOE ε4 allele (n=499, 35.4 %) whereas the non-carriers 
had none (n=910, 64.6 %). The screening phase was conducted in the Department of Public 
Health and General Practice in the University of Kuopio and the North Karelia Project Office 
in Joensuu. The clinical and differential diagnostic phases were conducted in the Memory 
Research Clinic of the Department of Neurology of the University of Kuopio and the North 
Karelia Central Hospital in Joensuu
4.1.3 second re-examination
The second re-examination of the CAIDE study was carried out during 2005-2008, and it was 
identical to the first re-examination with some minor modifications related to the screening 
criteria. All three study phases in Kuopio were conducted in the Brain Research Unit of the 
Clinical Research Center in the University of Kuopio. In Joensuu, the screening phase was car-
ried out in the North Karelia Project Office and the clinical and differential diagnostic phases 
in the North Karelia Central Hospital.    
4.1.4 diagnostic procedure
Cognitive status of the participants was determined at both re-examinations with a three step 
protocol including a screening phase, a clinical phase, and a differential diagnostic phase:
1) First during the screening phase the subject and an informant were interviewed and a 
trained study nurse carried out a preliminary cognitive testing. These tests included:
• Mini-Mental State Examination (MMSE) (Folstein et al. 1975) in the first re-ex-
amination and the Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD) neuropsychological test battery (Morris et al. 1989) in the second re-
examination
• Immediate word recall tests for episodic memory (Nyberg et al. 1997, Heun et al. 
1998)
• Category fluency test for semantic memory (Borkowski et al. 1967)
• Purdue Peg Board test and letter-digit substitution test for psychomotor speed 
(Tiffin 1968, Wechsler 1944)
• Stroop test for executive functioning (Stroop 1935)
• Prospective memory task (Einstein et al. 1997)
• Subjective memory rating (Bennett-Levy et al. 1980)
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2)  If the subject scored 24 or less in the MMSE, a further assessment was made in the 
clinical phase. Additional screening criteria used in the second re-examination to 
improve sensitivity to detect MCI and very mild dementia were: 1) MMSE 24 points 
or less, 2) decline in MMSE of three or more points since the first re-examination, 3) 
delayed recall word list test < 70 % in the Finnish version of CERAD test battery, or 
4) report of cognitive decline by the informant. Altogether 294 individuals fulfilled 
the screening criteria in the first re-examination, and 484 in the second re-examina-
tion. However, at this point some persons refused to participate in the clinical phase 
meaning that ultimately 254 persons (first re-examination) and 427 persons (second 
re-examination) proceeded to the second phase. In the clinical phase, the subjects 
went through a detailed physical examination carried out by a physician as well as 
performing a thorough neuropsychological testing conducted by a neuropsychologist. 
A review board consisting of the study physician and neuropsychologist, a senior 
neurologist and a senior neuropsychologist carefully evaluated all the available infor-
mation and ascertained the preliminary diagnoses. The individuals who were judged 
to have possible dementia or MCI were finally invited to be the subjects of differential 
diagnostic examinations in the third phase of the study.
3)  The differential diagnostic phase included brain computer tomography (CT)/MRI, 
relevant blood tests, chest radiograph, electrocardiogram, and CSF analysis if needed. 
All accumulated data were carefully re-evaluated by the review board before estab-
lishing the final diagnosis. Altogether 61 individuals were diagnosed with dementia, 
and 48 of those had AD at the first re-examination. At the second re-examination 68 
subjects were diagnosed with dementia (62 were incident dementia), and 57 of those 
had AD (52 incident). In addition, 82 subjects received a diagnosis of MCI at the first 
re-examination, and 103 persons (95 were incident MCI) at the second re-examination.
4.1.5 diagnostic criteria
The diagnosis of dementia was based on the DSM-IV criteria (American Psychiatric Association 
1994) and diagnoses of probable and possible AD were based on the NINCDS-ARDRA criteria 
(McKhann et al. 1984). The individuals diagnosed with AD displayed generalised and/or me-
dial temporal lobe atrophy, and none had any significant vascular pathology revealed by MRI. 
Isolated, minor lacunae or moderate white matter changes were not considered as exclusion 
criteria for AD. The AD patients scored four or less on the Hachinski Ischemia Scale (Hachinski 
et al. 1975).  The diagnosis of VaD was based on the NINDS-AIREN criteria (Roman et al. 
1993). Consensus criteria were used to diagnose other dementia types as follows: consensus 
diagnostic criteria for frontotemporal dementia (Neary et al. 1998), consortium for dementia 
with Lewy bodies (McKeith et al. 1996), and consensus criteria for alcohol related dementia 
(Oslin et al. 1998). 
The diagnosis of MCI was made according to a modified version of the Mayo Clinic AD 
Research Center criteria (Smith et al. 1996, Petersen et al. 1995). These included: 1) memory 
complaint by patient, family, or physician, 2) normal activities of daily living, 3) normal global 
cognitive function, 4) objective impairment of memory or other areas of cognitive function-
ing as evidenced by scores > 1.5 standard deviations (SD) below the age-appropriate mean, 5) 
Clinical Dementia Rating (CDR) score of 0.5, and 6) absence of dementia.
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4.1.6 register information
To estimate the effect of differential non-participation, information was acquired on the MCI 
and dementia diagnoses of the individuals from several other sources.  First, dementia diag-
noses of the non-participants were manually searched from medical records of local hospitals 
and health care centres after both re-examinations. Second, register data on medical diagnosis 
were available from three different national registers in Finland: the national hospital dis-
charge register which includes information on in-patient sojourns in public hospitals (i.e. main 
reasons of hospitalization) starting from 1967; the Social Insurance Institution’s register on the 
reimbursement of pharmaceutical expenses which includes information on the date when the 
person became entitled for reimbursement of AD drugs (donepezil, rivastigmine, galantamine, 
and memantine) and the dates of reimbursed drug purchases starting from 1999; and causes-
of-death register where the direct and underlying causes of death are recorded. The hospital 
discharge diagnoses and causes of death were coded using ICD-8 - ICD-10. ICD-8 was used in 
Finland during 1969-1986, ICD-9 during 1987-1995, and ICD-10 from 1996 onwards.
4.2 KAISER PERMANENTE
One study (study II) of the current thesis is based on a large, multiethnic, retrospective study 
cohort of members of the Kaiser Permanente Medical Care Program of Northern California. 
Kaiser Permanente is a non-profit, integrated health maintenance organization based in 
Oakland, California. It was founded in 1945, and it is one of the oldest and largest health 
maintenance organizations in the United States. The Division of Research (DOR) was founded 
in 1961. DOR’s research program is built on a base of rigorous epidemiologic investigation in 
a large, well-characterized population, and its major contributions have been in the areas of 
risk factor identification and prevention of diseases, including dementia. Kaiser Permanente 
of Northern California covers more than one fourth of the population in the geographic areas 
served, and the members are representative of the sociodemographics of the local population 
(Krieger 1992).
4.2.1 midlife examination 
The study cohort in study II comprises members of the Kaiser Permanente Medical Care 
Program of Northern California who participated in voluntary health examinations called 
the multiphasic health checkup (MHC) in San Francisco and Oakland during 1978-1985 when 
they were 50 to 60 years old (N=33 108). If members attended more than one MHC during this 
interval, data from the first visit were considered. The analytic cohort consisted of total of 21 
123 people who were still alive and members of the health plan in 1994 when electronic medical 
record diagnoses of dementia became available. People who had missing data on the smoking 
questionnaire (N=1045) were excluded. 
The purpose of the MHC was to collect a large amount of data on health habits and medical 
conditions of the subjects, and it was given as a part of routine medical care at all San Francisco 
and Oakland medical clinics. It included a detailed interview on health behavior, health sta-
tus, medication, and medical as well as family history. Several clinical measurements were 
carried out: participants’ height, weight, systolic and diastolic blood pressure were measured, 
and body mass index was calculated. In addition, a blood sample was drawn for determining 
serum cholesterol level. A high cholesterol level was defined as a total serum cholesterol ≥ 
240 mg/dL (to convert cholesterol to millimoles per liter, multiply by 0.0259). The participants 
were considered to have hypertension if they had one of the following: self-report of physician 
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diagnosed hypertension, use of antihypertensive medication, systolic blood pressure ≥ 140 
mmHg, or diastolic blood pressure ≥ 90 mmHg. Diabetes was defined by self-report of physi-
cian diagnosed diabetes, use of insulin or oral hypoglycemic drugs, a fasting glucose (last food 
eaten in ≥ 8 hours) of ≥ 140 mg/dL, or a non-fasting (last food eaten in ≤ 4 hours) glucose of ≥ 
200 mg/dL (to convert glucose to millimoles per liter, multiply by 0.0555). Stroke and cardio-
vascular disease were recorded from hospital discharge diagnoses (ICD-9 codes for ischemic 
stroke 433-438, hemorrhagic stroke 430-432, and for cardiovascular disease 410, 411, 413, 414, 
428, 440, 443, V717) from 1978 through the end of the study. The study was approved by the 
Internal Review Board of Kaiser Permanente.   
4.2.2 late-life evaluation of dementia diagnoses
The dementia diagnoses of the participants were derived from an electronic medical record 
database which was created in 1994 and implemented in all Kaiser Permanente medical centres 
and clinics in 1995. The medical record form was completed by the treating physician after 
every outpatient or inpatient encounter. The diagnoses considered in this study included both 
AD (n=1136) (ICD-9-CM code 331.0) and VaD (n=416) (ICD-9-CM code 290.4) which were made 
by a neurologist or neuropsychologist. General dementia diagnoses (n=5367) which addition-
ally included the diagnosis of unspecified dementia (ICD-9-CM code 290.0) were made by an 
internal medicine physician. The diagnoses were ascertained from January 1st, 1994 to July 
31st, 2008.
4.3 STATISTICAL ANALYSES AND FORMATION OF THE STUDY 
POPULATION
The sociodemographic and clinical characteristics of the participants were compared using 
χ2 -test for categorical variables and analysis of variance or t-test for continuous variables as 
appropriate.
4.3.1 study I
The first study investigated the association between midlife smoking and dementia/AD in the 
CAIDE population. At the time of this study, only data from the first re-examination of the 
CAIDE study was available. 
The subjects were categorized according to their midlife smoking habits into three groups: 
the subjects who 1) had never smoked (=never smokers, n=826, 58.2 %), 2) had last smoked over 
a year ago (=former smokers, n=272, 19.2 %), and 3) had smoked within the last year (=cur-
rent smokers, n=321, 22.6 %). The never smoker group was used as the reference category. 
Information on midlife smoking was available for 1419 (97.9 %) subjects who participated in the 
first re-examination. Data on smoking were missing for two demented persons (with AD) leav-
ing the total amount of dementia and AD diagnoses in the analyses as 59 and 46, respectively. 
Pack-years (the average number of cigarettes daily smoked divided by 20 and multiplied by 
the number of years of smoking) were also calculated to assess the subjects’ long-term expo-
sure to smoking. Pack-years could be calculated for 224 subjects (69.8 % of the current smokers), 
and they were dichotomized into two groups: those having smoked 1) less (n=147) or 2) more 
(n=77) than 20 pack-years. The first group was used as the reference category. The cut-off was 
based on previous studies indicating that the risk of dementia and AD might be higher after 
20 pack-years of smoking (Tyas et al. 2003, Reitz et al. 2007).
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Finally, it was also investigated how quitting smoking would affect the risk of developing 
dementia later in life. Comparable information on smoking from both midlife and the first re-
examination was available for 1327 persons (91.6 %). Of them 792 reported being never smokers 
at both time points, 87 current smokers at both time points, and 169 persons had quit smoking 
between the midlife and the late-life examinations. These analyses compared the quitters to 
those who reported being never smokers at both time points, and also to those who were cur-
rent smokers at both time points.
The impact of midlife smoking on the development of dementia/AD later in life was ana-
lyzed with logistic regression analysis resulting in odds ratios (ORs) with 95 % confidence 
intervals (CIs). First, the analyses were adjusted for potential sociodemographic confounders 
including age, sex, and education, and follow-up time (model 1). Second, also cardiovascular 
risk factors and events (midlife systolic blood pressure, serum cholesterol, and BMI, and late-
life myocardial infarction, stroke, and diabetes/impaired glucose tolerance (diagnosed prior 
to the re-examination)) as well as lung diseases (asthma or/and COPD diagnosed prior to the 
re-examination) and the APOE carrier status of the subject (presence of at least one APOE ε4 
allele) were taken into consideration (model 2). In addition, the analyses concerning the risk 
of both dementia and AD were repeated for the entire study sample including the data on the 
non-participants of the first re-examination derived from medical records (adjusted also for 
sociodemographic and midlife covariates). The total number of dementia cases was 117 and 
AD 76 in the whole study population (n=2000) when these diagnoses where taken into account. 
The possible modifying effects of the APOE carrier status and sex were investigated first 
by stratifying the analyses separately with these factors. Second, the possible interaction be-
tween smoking and the APOE carrier status or sex was tested by adding these interaction 
terms separately into the fully adjusted logistic regression models. Third, combined variables 
were created resulting in all the possible combinations of smoking and the APOE genotype 
as well as smoking and sex. In these analyses, the same possible confounders as used in the 
main analyses were taken into consideration. 
The participants with missing information for one or several covariates were excluded from 
the respective analyses. The statistical analyses were conducted using SPSS for Windows, 
release 16.0.
4.3.2 study II
The second study was intended to cross-validate the findings from the first study in a large, 
multiethnic cohort of 21 123 participants with the possibility to also examine various sub-
types of dementia. More specifically, this study investigated the association between smoking 
amount in middle age and the risk of dementia, AD, and also VaD later in life. For the analyses 
smoking was defined as a categorical variable with 6 levels: never smokers (n=10 205, 48.3 %), 
former smokers (n=6541, 31.0 %), smoking less than 0.5 pack per day (n=979, 4.6 %), 0.5-1 pack 
per day (n=1787, 8.5 %), 1-2 packs per day (n=1350, 6.4 %), and more than 2 packs per day (n=261, 
1.2 %). The never smoker group was used as the reference category. For cases, the calculated 
person-years in this study included age (as time scale) in January 1st, 1994, until the age at 
diagnosis of dementia, AD, or VaD and, for controls, until age at death, age at date of end of 
Kaiser membership (as defined by a lag in health plan membership of 90 days or more), or age 
at end of follow-up, July 31st, 2008. Incidence rates were determined specifically for smoking 
categories. Age-adjusted incidence rates were calculated using the whole cohort as the stand-
ard population with 4 age groups including younger than 77 years, 77 to 81 years, 81 to 85 
years, and older than 85 years. 
36
Cox proportional hazards model (age as the time scale) resulting in hazard ratios (HRs) with 
95 % CIs was used to investigate the relationship between midlife smoking and dementia, AD, 
and VaD. Participants were censored according to age at dementia diagnosis, age at date of 
death, age at lag in health plan membership, or age at the end of follow-up, July 31st, 2008. The 
models were first adjusted for potential sociodemographic confounders age (as time scale), sex, 
education (categorized as high school, trade school, college 1-2 years, college 3-4 years, and 
postgraduate, with grade school as a reference), race (entered as white, Asian, and other, with 
African American as a reference group), and marital status (classified as never married and di-
vorced/widowed/separated, with married as a reference group). Second, the models were also 
adjusted for midlife BMI, hyperlipidemia, diabetes, hypertension, heart disease, and stroke 
(yes/no) during the follow-up. Finally, the analyses were additionally adjusted for midlife al-
cohol drinking (classified as former, occasionally, 1-2 drinks per day, and > 3 drinks per day, 
with never drinkers as a reference group). To examine whether the association between smok-
ing and dementia, AD, or VaD was modified by sex or race, interaction terms were added to 
the Cox models. Because stroke is a robust predictor of dementia and also highly associated 
with smoking the association between smoking and dementia risk was additionally examined 
separately for those with and without a stroke; the final multivariate models were adjusted for 
both stroke during dementia follow-up (stroke from 1994 to 2008) or intercurrent stroke (stroke 
between baseline and the start of dementia ascertainment from 1978 to end of 1993). 
Individuals with a dementia diagnosis other than the one under investigation were exclud-
ed from the analyses regarding AD or VaD separately (AD models n=17 360 and VaD models 
n=16 294). All analyses were carried out using SAS version 9.1 (SAS Institute, Cary, NC).
4.3.3 study III
At the time of the third study, data on the second re-examination of the CAIDE had become 
available and thus were used in the study. This study examined the association between midlife 
and late-life self-reported COPD and asthma and the risk of cognitive impairment (MCI and 
dementia) in the CAIDE cohort. Information on pulmonary diseases was inquired in the self-
administered questionnaire conducted at every examination visit. There were questions asking if 
the person had a diagnosis of pulmonary emphysema or chronic bronchitis (yes/no) (categorised 
in the present study as COPD) or asthma (yes/no). At the midlife examination, there were 71 sub-
jects (4.7 %) who reported having COPD and 25 (1.7 %) had asthma. At the first re-examination, 
95 individuals (7.0 %) had previously received a diagnosis of COPD and 185 (13.7 %) had been 
given a diagnosis of asthma. These diseases were analysed separately and also combined as one 
pulmonary disease variable. Accordingly, at midlife, altogether 86 (5.8 %) individuals reported 
having either one of these pulmonary diseases and 237 (17.5 %) persons had received the diag-
nosis prior to the first re-examination. 
The analytic cohort of the third study comprised persons who participated in the first or 
second or both re-examinations (N=1511, 75.6 %). Subjects were categorised as having MCI 
(N=172) or dementia (N=117). Subjects with first MCI and later dementia were categorised as 
MCI. Since cognition is actually a continuum and MCI is regarded as a precursor of dementia, 
in this study MCI and dementia were ultimately combined as one outcome variable referred to 
as cognitive impairment (N= 289). The participants who had neither MCI nor dementia formed 
the control group (N=1222). 
Multivariate Cox regression models were used to investigate the association between COPD, 
asthma, and both pulmonary diseases combined and the later risk of cognitive impairment 
(MCI or dementia). In the Cox regression models (follow-up time as time scale) the participants 
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were censored according to follow-up time at cognitive impairment diagnosis, at time of the 
last study visit or date of death for controls, or at end of the study (December 18th, 2008) for 
non-participants. First, the analyses were adjusted for sociodemographic confounders age, sex, 
and education (model 1). In model 2, midlife smoking status (yes/no) was added to the model. 
In model 3, also the APOE ε4 carrier status (yes/no), midlife self-reported physical activity (sed-
entary = leisure-time physical activity < 2 times/week or active = leisure-time physical activity 
≥ 2 times/week), systolic blood pressure, BMI, and total serum cholesterol, and the number of 
late-life vascular diseases (myocardial infarction, stroke, and diabetes/impaired glucose toler-
ance in late-life) were included. 
The analyses were carried out separately for midlife and late-life pulmonary diseases. In 
the analyses regarding the late-life pulmonary diseases, the individuals with midlife pulmo-
nary diseases were excluded. In addition, for the purpose of examining incident dementia, the 
outcome in these analyses was considered only from the second re-examination, and those 
subjects who were cognitively impaired (MCI or dementia diagnose) in the first re-examination 
(N=143) were excluded.
To include also the non-participants in the supplementary analyses information was gath-
ered on the MCI and dementia diagnoses of the individuals from several sources of register 
information as described earlier in 3.1.6. Thus finally, information on the MCI and dementia 
diagnoses obtained from all the available sources was combined with the diagnoses of the 
CAIDE study participants resulting in a total of 178 MCI and 359 dementia cases in the whole 
cohort (N=2000). Then the midlife analyses were repeated among the entire cohort (adjusted 
for the sociodemographic and midlife covariates). 
Subjects with missing values for any of the variables in the respective model were also ex-
cluded from the analyses. All analyses were conducted with PASW Statistics, release 19.
4.3.4 study Iv
The fourth study examined the association between midlife and late-life heart diseases in-
cluding atrial fibrillation (AF), heart failure (HF), and coronary heart disease (CHD) and the 
risk of dementia and AD in the CAIDE cohort. Data from both re-examinations of the CAIDE 
were used in the analyses. In order to obtain as accurate information as possible on the heart 
disease diagnoses of the subjects, information was acquired from several sources. First, in-
formation on heart diseases was inquired in the self-administered questionnaire presented 
at every examination visit. There were questions if the person had had a myocardial infarc-
tion (yes/no) or angina pectoris (yes/no), and if answered yes, that subject was categorised as 
having CHD. There was also a question about diagnosis of HF (yes/no), but information on a 
possible diagnosis of AF was not asked in the self-administered questionnaires. Diagnoses of 
CHD (ICD-8 codes: 410-414, ICD-9 codes: 410-414, and ICD-10 codes: I20-I25), AF (ICD-8 codes: 
427.92, ICD-9 codes: 4273A, and ICD-10 codes: I48) and HF (ICD-8 codes: 427.00, 427.10, 782.40, 
ICD-9 codes: 428, 4029B, 4254A, 4148, and ICD-10 codes: I50, I50.0, I50.1, I50.9, I11.0, I13.0, I13.2) 
were also sought from the national hospital discharge register described above. Ultimately, all 
these data were combined to create the corresponding heart disease variables. Thus, the CHD 
and HF variables included the self-reported data as well as the register data, whereas the AF 
variable was based only on register data. In addition, as these heart diseases often co-exist, 
one combination variable was created of having at least one of these heart diseases. At midlife, 
altogether 98 persons had CHD, 55 had HF, 7 had AF, and 133 subjects had at least one of these 
diagnoses. At the first re-examination, a total of 193 persons had a diagnosis of CHD, 86 had 
HF, 34 had AF, and 233 participants had at least one of these diagnoses.
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The analytic cohort of the fourth study is same as that investigated in the third study. 
However, in an attempt to refine the information on dementia diagnoses of all the individuals, 
these were also checked from the previously described registers. One individual was excluded 
from the cohort because of uncertainty of the time of the dementia diagnosis leaving a total 
of 1510 participants (75.5 %) in the midlife analyses. Furthermore, 8 subjects were identified as 
controls in the CAIDE study but had received a diagnosis of dementia based on the registries. 
These persons were considered as demented in these analyses. There were 127 (8.4 %) persons 
with dementia (of which 101 had AD) and 1383 controls in the cohort.
Flexible parametric survival models were used to investigate the association between 
midlife and late-life AF, HF, CHD, and all heart diseases combined and the later risk of 
dementia and AD. The model was chosen because it makes it possible to take into account 
the uncertainty of the precise timepoint when the outcome occurred. This was considered 
necessary due to the long follow-up times between baseline and re-examinations. Flexible 
parametric models for dementia-free survival time were fitted using Stata 11.2 (Stata Corp 
College Station, TX, USA) and stpm program. In the model, age (years) at last visit for con-
trols, and age at first visit with dementia or age when dementia first appeared in registers 
(whichever came first) for cases, was considered as survival time a for all subjects. In addi-
tion, individuals who died or were lost to follow-up were censored at time a. A lower limit 
was also considered for survival time: assuming that the dementia diagnosed in the last visit 
was actually started before the last visit and after the visit before the last visit (a0). It was 
also assumed that individual could not be demented before the age of 60. So, max(60, a0) 
was considered as the lower limit for survival time, where a0 was the subject’s age (years) at 
the visit before the last visit. Number of knots (i.e. shape of estimated spline) was selected 
on the basis of Akaike s´ information criteria (AIC). Models with 1 to 5 knots were estimated. 
The model with the lowest AIC value was considered as the best fitting model. However, it 
was decided also to take into consideration the model parsimony: in case of almost identical 
AIC values the model selected was with the fewest number of knots. For some models, knot 
selection was not possible using evaluation AIC values (estimation was not possible due to 
computational problems or due to inadequate model results). In these cases it was assumed 
that fewer number of knots would be adequate. The choice of number of knots was also 
verified by plotting smoothed baseline hazard of lower and upper bound survival times and 
predicted hazard function against survival times and it was checked if the plot displayed 
evidence of more knots. The plot described above was also used to evaluate the model fit 
against smoothed baseline hazard of lower and upper bound survival times. If predicted 
hazard function was too complex compared to the smoothed baseline hazard of lower and 
upper bound survival times or if some of the predicted hazard values were negative, the 
model with the next best fit was selected on the basis of AIC and model parsimony.
All the analyses were firstly adjusted for the sociodemographic confounders sex and edu-
cation in the model 1. In model 2, also midlife systolic blood pressure, total serum cholesterol 
level, and BMI value were added to the model. In model 3, the APOE ε4 carrier status (0 = no/1 
= yes), midlife smoking status (0 = no/1 = yes) and self-reported physical activity (0 = leisure-
time physical activity < 2 times/week or 1 = leisure-time physical activity ≥ 2 times/week) 
were included as covariates as well. The final model 4 was additionally adjusted for diabetes/
impaired glucose tolerance (0 = no/1 = yes) and stroke (0 = no/1 = yes) at late-life. 
The analyses were carried out separately for midlife and late-life heart diseases. In the 
analyses examining relationship between heart diseases at late-life (diagnosed prior to the first 
re-examination) and incident dementia at the second re-examination the subjects who were 
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already demented or non-participating in the first re-examination were excluded. In these 
analyses, there were 46 (6.2 %) demented participants (of which 40 had AD) and 692 controls. 
There were some missing data concerning information on education, APOE status, midlife 
smoking and physical activity, and late-life diabetes and stroke. Since it was considered that 
the missing data might not be random the missing values were replaced with a mean value 
regarding education (mean=8.58 years) and with a value of 0.5 regarding the other categori-
cal variables. Data on education was missing for 25 persons, APOE status for 131 persons, 
midlife smoking for 33 persons, midlife physical activity for 42 persons, late-life diabetes for 
139 persons, and late-life stroke for 137 persons in the study cohort. The main analyses were 
also repeated without the imputed data, including only the subjects with no missing values in 
the respective analyses, to check for the effect of imputation on the results.
To explore possible interaction with the APOE ε4 allele, the analyses were stratified accord-
ing to the APOE ε4 carrier status. In the analyses regarding AD as an outcome, other forms 
of dementia were censored at the time of the diagnosis. Finally, to evaluate the effect of non-
participation, the main analyses were additionally repeated among the entire cohort including 
also data from the non-participants derived from the registries described in 3.1.6. (adjusted for 
sociodemographic and midlife vascular factors). There were a total of 408 (20.4 %) persons with 
dementia in these analyses.
All statistical analyses were performed with PASW Statistics, release 19 and Stata 11.2 (Stata 
Corp College Station, TX, USA).
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5 Results
5.1 CHARACTERISTICS OF THE CAIDE STUDY POPULATION
The mean age of the participants at baseline (n=2000) was 50.6 years (SD 6.0, range 39.2 – 64.1), at 
the first re-examination (n=1449) 71.3 years (SD 4.0, range 65.1 – 80.4), and at the second re-exam-
ination (n=909) 78.6 years (SD 3.7, range 72.3 – 89.6). There were 900 (62.1 %) women and 549 (37.9 
%) men at the first re-examination, and 590 (64.9 %) women and 319 (35.1 %) men at the second 
re-examination. The follow-up time of the participants at the first re-examination was on aver-
age 20.9 years (SD 4.9) and at the second re-examination 28.5 years (SD 5.0). The characteristics of 
the participants of the first and/or second re-examination (n=1510) and non-participants (n=490) 
of the study are shown in Table 5. The persons who did not participate in any re-examinations 
were older, had less education, had had higher values of systolic blood pressure, total serum cho-
lesterol levels, and BMI at midlife, and were more often smokers at midlife than the participants.
Table 5. Sociodemographic and clinical characteristics of the participants and non-participants of 
the re-examinations
Participants 
(N=1510)
Non-
participants 
(N=490)
p-value
Age, years*
-at baseline (N=1998) 50.3 (6.0) 51.5 (5.9)
0.000
Sex, N (%) (N=2000)
-Men
-Women
568 (37.6)
942 (62.4)
182 (37.1)
308 (62.9)
0.85
Education, years* (N=1953) 8.6 (3.4) 7.5 (3.1) 0.000
Midlife systolic blood pressure, mmHg* (N=2000) 144.3 (20.0) 151.2 (21.4) 0.000
Midlife total cholesterol, mmol/l* (N=2000) 6.8 (1.2) 7.0 (1.3) 0.002
Midlife body mass index, kg/m2* (N=2000) 26.6 (3.8) 27.4 (4.4) 0.000
Midlife smoking, N (%) (N=1954)
-Yes 340 (23.0) 141 (29.6)
0.004
Physical activity, N (%) (N=1935)
-Sedentary
-Active
874 (59.5)
594 (40.5)
280 (60.0)
187 (40.0)
0.87
* Values are expressed as means (SD), and t-test was used; otherwise the χ2 test was used 
5.2 SMOKING AND DEMENTIA AND ALZHEIMER’S DISEASE IN 
CAIDE (STUDY I)
5.2.1 characteristics of the study population according to midlife smoking status
Sociodemographic and clinical characteristics of the study population in study I according to 
their midlife smoking status are shown in Table 6. Current smokers at midlife were younger 
and had a longer follow-up time than the former or non-smokers. Both the current and the 
former smokers were more often men, and had more often a history of myocardial infarction 
than their non-smoking counterparts. There were no differences in other sociodemographic 
or clinical characteristics between the midlife smoking groups. The proportion of participants 
with dementia (n=16, 5.0 %) and AD (n=14, 4.6 %) at the first re-examination tended to be greater 
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among the current smokers than among the never (dementia n=33, 4.0 %, AD n=25, 3.1 %) or 
former smokers (dementia n=10, 3.7 %, AD n=7, 2.6 %), but the differences between the groups 
did not reach statistical significance. 
With respect to the non-participants (n=551) in the first re-examination, they were slightly 
older, less educated, and had had higher blood pressure and cholesterol levels at midlife than the 
participants. They were also more often current smokers at midlife (29.9 % vs. 22.6 %) and less 
often never-smokers (53.6 % vs. 58.2 %) or former smokers (16.4 % vs. 19.2 %). The sex distribution 
was similar in both groups. Furthermore, there were more demented persons (diagnoses derived 
from medical records) among the non-participants (8.5 %) than among the participants (4.8 %).
Table 6. Sociodemographic and clinical characteristics of the subjects in study I according to their 
midlife smoking status
Never 
(n=826)
Former 
(n=272)
Current 
(n=321)
P-values
Characteristics
Age at baseline, years* 50.7 (6.1) 51.1 (5.9) 48.8 (5.5) p1=0.98, p2=0.000, 
p3=0.000
Age at 1st re-examination, years* 71.4 (4.1) 71.5 (4.2) 70.8 (3.7) p1=1.00, p2=0.06, p3=0.09
Men/women, n (%) 130 
(15.7)/696 
(84.3)
196 
(72.1)/76 
(27.9)
204 
(63.6)/117 
(36.4)
p1=0.000, p2=0.000, 
p3=0.03
Follow-up time, years* 20.7 (5.0) 20.4 (5.0) 22.0 (4.4) p1=1.00, p2=0.000, 
p3=0.000
Education, years* 8.5 (3.4) 8.9 (3.9) 8.5 (3.3) p1=0.42, p2=1.00, p3=0.61
APOE ε4 carriers/non-carriers, n (%) 276 
(34.4)/526 
(65.6)
97 
(36.7)/167 
(63.3)
120 
(38.2)/194 
(61.8)
p1=0.49, p2=0.23, p3=0.72
Baseline
Systolic blood pressure, mmHg* 144.5 
(20.5)
145.7 
(20.4)
143.6 
(18.9)
p1=1.00, p2=1.00, p3=0.62
Diastolic blood pressure, mmHg* 88.8 (10.8) 90.4 (11.1) 89.5 (11.5) p1=0.10, p2=1.00, p3=0.88
Total serum cholesterol, mmol/l* 6.8 (1.2) 6.7 (1.2) 6.7 (1.2) p1=1.00, p2=0.63, p3=0.98
Body mass index, kg/m2* 26.6 (3.8) 26.8 (3.5) 26.1 (3.4) p1=1.00, p2=0.12, p3=0.12
1st re-examination
Myocardial infarction, n (%) 89 (11.0) 52 (19.3) 64 (20.3) p1=0.000, p2=0.000, 
p3=0.78
Stroke, n (%) 51 (6.4) 20 (7.5) 27 (8.7) p1=0.52, p2=0.17, p3=0.59
Diabetes mellitus or impaired glucose 
tolerance, n (%)
80 (10.0) 34 (12.8) 35 (11.2) p1=0.21, p2=0.56, p3=0.56
Lung diseases (asthma/COPD), n (%) 108 (13.7) 39 (14.9) 51 (16.4) p1=0.62, p2=0.24, p3=0.62
Dementia, n (%) 33 (4.0) 10 (3.7) 16 (5.0) p1=0.81, p2=0.46, p3=0.44
Alzheimer’s disease, n (%) 25 (3.1) 7 (2.6) 14 (4.6) p1=0.68, p2=0.25, p3=0.22
 
*Values are expressed as means (SD), and analysis of variance was used; otherwise the χ2 test was 
used.
P1 is the p-value for the differences between never and former smokers. 
P2 is the p-value for the differences between never and current smokers. 
P3 is the p-value for the differences between former and current smokers. 
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5.2.2 midlife smoking and the risk of dementia and ad
Current smoking at midlife tended to increase the risk of dementia and AD later in life (at 
the time of the first re-examination), but the effect was not statistically significant among all 
participants (Table 7). When the analyses were repeated among the entire study sample also 
including the non-participants, the results remained statistically non-significant (for dementia 
OR 0.86, 95% CI 0.49-1.52 and for AD OR 1.11, 95% CI 0.56-2.20). Next it was examined whether 
APOE ε4 could modify the association by stratifying the analyses according to the partici-
pants’ APOE carrier status. Interestingly, in these analyses, current smoking at midlife was 
found out to increase the risk of both dementia and AD later in life only among the APOE ε4 
carriers. Among the APOE ε4 non-carriers, there was no association between smoking and the 
disease risk. The multiplicative interaction term between midlife smoking and the APOE car-
rier status was significant in the fully adjusted model (for dementia p=0.006 and for AD p=0.02). 
In the analyses using a combined variable with all the possible combinations of smoking and 
the APOE genotype, those individuals who were both APOE ε4 carriers as well as smokers had 
an OR of 5.33 (95% CI 1.96-14.48; Figure 2) to become demented later in life as compared to the 
non-smoking, non-carriers. With respect to AD, the risk increase was over 7-fold (OR 7.62, 95% 
CI 2.53-22.95; Figure 3). There was no effect modification found for sex in the stratified analy-
ses, or analyses for the combined variable including smoking and sex. The interaction term 
between smoking and sex was also non-significant (for dementia p=0.48 and for AD p=0.45).
5.2.3 pack-years and the risk of dementia and ad
To assess whether the amount of smoked cigarettes influences the disease risk it was decided 
to examine the association between pack-years of smoking at midlife and the subsequent risk 
of dementia/AD later in life. Pack-years could be calculated for 224 subjects (69.8 % of the cur-
rent smokers). In these analyses, there was a non-significant tendency towards an increased 
risk of both dementia (OR 1.64, 95% CI 0.21-12.78, p=0.64) and AD (OR 1.66, 95% CI 0.21-12.94, 
p=0.63) with having smoked at least 20 pack-years, but the association did not reach statistical 
significance, probably due to compromised statistical power in these analyses.
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Table 7. Midlife smoking and the risk of dementia and Alzheimer’s disease
Odds Ratio (95% Confidence Interval)
All participants APOE ε4 carrier APOE ε4 non-carrier
DEMENTIA n=1419, dementia 59 n=493, dementia 31 n=887, dementia 26
Crude model
never 1 1 1
former 0.92 (0.45-1.89) 1.87 (0.71-4.98) 0.52 (0.15-1.78)
current 1.26 (0.68-2.32) 2.93 (1.27-6.74) 0.44 (0.13-1.52)
Model 1
never 1 1 1
former 0.65 (0.28-1.54) 1.21 (0.36-4.10) 0.42 (0.10-1.74)
current 1.20 (0.58-2.50) 3.55 (1.23-10.19) 0.40 (0.10-1.62)
Model 2
never 1 1 1
former 0.71 (0.26-1.90) 1.58 (0.41-6.04) 0.30 (0.05-1.65)
current 1.54 (0.67-3.56) 4.93 (1.51-16.11) 0.36 (0.08-1.62)
AD n=1367, AD 46 n=477, AD 25 n=860, AD 21
Crude model
never 1 1 1
former 0.84 (0.36-1.96) 1.19 (0.36-3.88) 0.61 (0.17-2.13)
current 1.47 (0.76-2.87) 2.79 (1.15-6.76) 0.54 (0.16-1.89)
Model 1
never 1 1 1
former 0.67 (0.25-1.81) 0.80 (0.19-3.33) 0.52 (0.12-2.31)
current 1.68 (0.75-3.78) 4.33 (1.37-13.68) 0.56 (0.13-2.38)
Model 2
never 1 1 1
former 0.72 (0.24-2.17) 1.23 (0.27-5.54) 0.40 (0.07-2.40)
current 2.17 (0.87-5.36) 6.56 (1.80-23.94) 0.56 (0.11-2.88)
  
Model 1 adjusted for age, sex, education, and follow-up time 
Model 2 adjusted additionally for APOE ε4 carrier status (unstratified analyses), systolic blood pressure, 
serum cholesterol, BMI, and history of myocardial infarction, stroke, diabetes/impaired glucose tolerance, 
and lung diseases
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Figure 2. Combined effect of midlife smoking and the APOE ε4 carrier status on the risk of de-
mentia later in life. Values are ORs from the logistic regression analysis adjusted for age, sex, 
education, follow-up time, midlife systolic blood pressure, serum cholesterol level, and BMI, and 
late-life myocardial infarction, stroke, diabetes/impaired glucose tolerance, and lung diseases.
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Figure 3. Combined effect of midlife smoking and the APOE ε4 carrier status on the risk of AD 
later in life. Values are ORs from the logistic regression analysis adjusted for age, sex, education, 
follow-up time, midlife systolic blood pressure, serum cholesterol level, and BMI, and late-life 
myocardial infarction, stroke, diabetes/impaired glucose tolerance, and lung diseases.
5.2.4 Quitting smoking and the risk of dementia and AD
The final part of this study investigated how quitting smoking after midlife would affect the 
risk of developing dementia/AD later in life. Among all participants, the subjects who quit 
smoking (n=169) between midlife and late-life examinations had a similar risk of developing 
dementia (OR 1.31, 95% CI 0.43-4.06, adjustments as in model 2) and AD (1.66, 95% CI 0.47-5.81) 
as those persons who were never smokers at both time points. However, when the analyses 
were stratified according to the APOE carrier status, the APOE ε4 carriers who had quit had 
an increased risk of dementia (4.76, 95% CI 1.01-22.47) and a tendency towards an increased 
risk of AD (5.40, 95% CI 0.96-30.21) compared to never smokers. There were no significant dif-
ferences between the persons who quit smoking and those who were current smokers at both 
time points.
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5.3 SMOKING AND ALZHEIMER’S DISEASE AND VASCULAR DE-
MENTIA IN KAISER PERMANENTE (STUDY II)
5.3.1 characteristics of the study population according to cognitive status
In the second study, a total of 5367 (25.4 %) persons were diagnosed with dementia (AD 1136 
cases, VaD 416 cases) during a mean follow-up time of 23.1 years (SD 5.1). The mean age of the 
participants at baseline was 58.0 years (SD 5.4) and at the time of the dementia diagnosis, 81.5 
years (SD 5.9). In all, 12 031 (57.0 %) were women and 9092 (43.0 %) were men. The sociode-
mographic and clinical characteristics of the study population according to cognitive status 
are shown in Table 8. As expected, those who were diagnosed with dementia were older, had 
fewer years of education and were more likely to be women than the non-demented individu-
als. There were differences in the occurrence of dementia between ethnic groups; compared 
with whites, African Americans were more likely to have a dementia diagnosis, while Asians 
were less likely. In addition, a higher percentage of divorced, widowed or separated persons, 
and a higher percentage of never drinkers were found among those with a dementia diagnosis. 
Dementia was also associated with a greater likelihood of having a higher mean midlife BMI 
value and all comorbidities.
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Table 8. Sociodemographic and clinical characteristics of the participants according to cognitive 
status in study II
Characteristics Dementia 
n=5367
Non-dementia 
n=15 756
All 
n=21 123
p-value
Age at baseline* 60.07 (5.32) 57.31 (5.28) 58.01 (5.42) < 0.001
Age at dementia* 81.45 (5.85) NA 81.45 (5.85) NA
Follow-up time* 21.37 (4.27) 23.72 (5.26) 23.12 (5.13) < 0.001
Age at 1/1/1994* 73.95 (5.51) 70.81 (5.69) 71.61 (5.81) < 0.001
Age at censor date* 81.45 (5.85) 81.03 (6.3) 81.14 (6.2) < 0.001
Gender, n (%) < 0.001
Male 2131 (39.71) 6961 (44.18) 9092 (43.04)
Race, n (%) < 0.001
Missing 8 (0.15) 21 (0.13) 29 (0.14)
African American 1427 (26.59) 3485 (22.12) 4912 (23.25)
White 3411 (63.56) 9956 (63.19) 13 367 (63.28)
Asian 321 (5.98) 1569 (9.96) 1890 (8.95)
Other 200 (3.73) 725 (4.6) 925 (4.38)
Education, n (%) < 0.001
Missing 65 (1.21) 120 (0.76) 185 (0.88)
Elementary or grade school 603 (11.24) 1413 (8.97) 2016 (9.54)
High school 1642 (30.59) 4554 (28.9) 6196 (29.33)
Trade/business school 520 (9.69) 1460 (9.27) 1980 (9.37)
College 1-2 years 1130 (21.05) 3524 (22.37) 4654 (22.03)
College 3-4 years 575 (10.71) 2017 (12.8) 2592 (12.27)
Postgraduate 832 (15.5) 2668 (16.93) 3500 (16.57)
Marriage, n (%) 0.002
Missing 11 (0.2) 31 (0.2) 42 (0.2)
Married 3833 (71.42) 11 557 (73.35) 15 390 (72.86)
Never married 218 (4.06) 718 (4.56) 936 (4.43)
Divorced/widowed/separated 1305 (24.32) 3450 (21.9) 4755 (22.51)
Alcohol Drinking, n (%) < 0.001
Missing 90 (1.68) 227 (1.44) 317 (1.5)
Never 896 (16.69) 2287 (14.52) 3183 (15.07)
Former 197 (3.67) 633 (4.02) 830 (3.93)
Occasionally 2778 (51.76) 8088 (51.33) 10 866 (51.44)
1-2 drinks/day 1051 (19.58) 3235 (20.53) 4286 (20.29)
≥ 3 drinks/day 355 (6.61) 1286 (8.16) 1641 (7.77)
Comorbidity
Baseline body mass index* 26.24 (4.5) 25.94 (4.4) 26.02 (4.5) < 0.001
Baseline hypertension, n (%) 2276 (42.4) 5798 (36.8) 8074 (38.2) < 0.001
Baseline hyperlipidemia, n (%) 3092 (57.6) 8180 (51.9) 11 272 (53.3) < 0.001
Diabetes, n (%) 428 (7.9) 1010 (6.4) 1438 (6.8) < 0.001
Heart Disease, n (%) 371 (6.9) 950 (6.03) 1321 (6.2) 0.02
Stroke from 1994-2008, n (%) 55 (1.0) 119 (0.7) 174 (0.8) 0.06
Stroke from 1978-1993, n (%) 293 (5.4) 522 (3.3) 815 (3.9) < 0.001
Smoking, n (%) < 0.001
Never 2724 (50.7) 7481 (47.4) 10 205 (48.3)
Former 1628 (30.3) 4913 (31.1) 6541 (30.9)
< 0.5 pack/day 234 (4.3) 745 (4.7) 979 (4.6)
0.5-1 pack/day 435 (8.1) 1352 (8.5) 1787 (8.4)
1-2 packs/day 283 (5.27) 1067 (6.77) 1350 (6.39) 
≥ 2 packs/day 63 (1.1) 198 (1.2) 261 (1.2) 
*Values are expressed as means (SD), and analysis of variance was used; otherwise the χ2 test was 
used. Abbreviations: NA=not available
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5.3.2 midlife smoking and the risk of dementia
Although both the crude incidence rates and age-adjusted incidence rates did not increase in 
a linear fashion according to smoking levels, there was a dramatic increase in the incidence of 
dementia found for those heavy smoking individuals who reported smoking more than 2 packs 
per day at midlife (Table 9). The calculated incidence rate of dementia in those individuals was 
312.206 (95% CI 235.11-389.3) and the age-adjusted incidence rate was even higher, 786.42 (95% 
CI 481.23-1091.61) per 10 000 person-years. In the unadjusted Cox proportional hazards model 
(adjusted for age as time scale), heavy smoking at midlife doubled the later risk of dementia as 
compared to the situation in non-smokers. The risk increase was unchanged in the fully adjusted 
multivariate model; using the non-smokers as a reference group, the HR (95% CI) was 2.14 (1.65-
2.78) for those smoking ≥ 2 packs per day, 1.44 (1.26-1.64) for 1-2 packs per day, and 1.37 (1.23-1.52) 
for 0.5-1 pack per day (Figure 4). Those who had previously smoked (HR 1.00, 95% CI 0.94-1.07) 
or who smoked less than 0.5 a pack per day (HR 1.04, 95% CI 0.91-1.20) in midlife had a demen-
tia risk similar to non-smokers. An additional fully adjusted multivariate model was conducted 
to control only for stroke occurring between baseline and the start of the dementia assessment 
(intercurrent stroke), to consider the potential confounding or mediating effects of stroke which 
had happened prior to dementia on the smoking-dementia association. These results were not 
markedly different than the prior model: compared to never smokers the HR (95% CI) was 2.12 
(1.64-2.75) for those smoking ≥ 2 packs per day, 1.43 (1.26-1.63) for 1-2 packs per day, and 1.36 (1.22-
1.51) for 0.5-1 pack per day. Former smoking (HR 1.00, 95% CI 0.94-1.07) or smoking less than 0.5 
pack per day (HR 1.05, 95% CI 0.91-1.20) was not associated with dementia risk.
5.3.3 midlife smoking and the risk of ad
With respect to AD, the disease risk was also doubled among the midlife heavy smokers 
compared to those not smoking. In the fully adjusted Cox model, the association remained 
the same (HR 2.57, 95% CI 1.63-4.03, Figure 5). For those smoking 1-2 packs (HR 1.18, 95% CI 
0.92-1.52) or 0.5-1 pack (HR 1.11, 95% CI 0.90-1.36) per day, the risk increase was borderline sig-
nificant, whereas former smoking (HR 1.00, 95% CI 0.89-1.13) or smoking less than 0.5 a pack 
(HR 0.80, 95% CI 0.61-1.06) per day in midlife was not associated with any risk of AD later in 
life as compared to non-smokers.
Table 9. Age-adjusted incidence rates and crude proportional hazards of dementia, AD, and VaD 
risk by midlife smoking status
Smoking 
status
No. of 
dementia 
cases
Age-adjusted 
incidence rate 
per 10 000 
person-years 
(95% CI)
Dementia
HR (95% CI)
AD 
HR (95% CI)
VaD
HR (95% CI)
Never 2724 (AD 590, 
VaD 210)
409.03 
(392.02-426.03) 1 (reference) 1 (reference) 1 (reference)
Former 1628 (AD 351, 
VaD 124)
403.08 
(381.05-425.11)
0.99 (0.93-1.06) 0.99 (0.89-1.11) 0.96 (0.79-1.16)
< 0.5 pack/day 234 (AD 39, 
VaD 17)
398.19 
(337.64-458.75)
1.08 (0.94-1.23) 0.85 (0.65-1.11) 1.10 (0.73-1.66)
0.5-1 pack/day 435 (AD 89, 
VaD 31)
483.59 
(425.64-541.54)
1.34 (1.21-1.48) 1.09 (0.89-1.33) 1.16 (0.83-1.62)
1-2 packs/day 283 (AD 50, 
VaD 29)
489.14 
(410.44-567.85)
1.37 (1.21-1.55) 1.17 (0.92-1.48) 1.44 (1.00-2.08)
≥ 2 packs/day 63 (AD 17, 
VaD 5)
786.42 
(481.23-1091.61)
2.01 (1.57-2.58) 2.36 (1.54-3.61) 2.02 (0.99-4.55)
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Figure 4. The risk of dementia according to midlife smoking status. Values are HRs from Cox 
proportional hazards model adjusted for age (as time scale), sex, education, race, marital status, 
hypertension, high cholesterol level, BMI, diabetes, heart disease, stroke, and alcohol drinking.
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Figure 5. The risk of AD according to midlife smoking status. Values are HRs from Cox propor-
tional hazards model adjusted for age (as time scale), sex, education, race, marital status, hyper-
tension, high cholesterol level, BMI, diabetes, heart disease, stroke, and alcohol drinking.
5.3.4 midlife smoking and the risk of vad
Next it was decided to examine whether midlife smoking would also increase the risk of VaD. 
Despite the smaller number of VaD cases, a two-fold disease risk was also detected among the 
midlife heavy smokers compared to the non-smokers. Even after controlling for many poten-
tial vascular confounding factors, in the fully adjusted Cox model, those individuals smoking 
more than 2 packs per day at midlife were almost three times (HR 2.72, 95% CI 1.20-6.18) more 
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likely to develop VaD later in life than the non-smoking individuals (Figure 6). The observed 
risk increase was borderline significant for those smoking 1-2 packs (HR 1.42, 95% CI 0.95-2.13) 
per day. Former smoking (HR 0.99, 95% CI 0.80-1.22), smoking less than 0.5 a pack (HR 1.05, 
95% CI 0.69-1.61), or 0.5-1 pack (HR 1.20, 95% CI 0.84-1.70) per day at midlife did not increase 
the later risk of VaD as compared to the non-smokers.
5.3.5 Interaction between smoking and race or sex
There were no significant interaction terms of smoking times sex or smoking times race (p 
values > 0.05). Post hoc stratified analyses did not reveal any trends that would have hinted at 
differences in the association between smoking and dementia according to race or sex.
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Figure 6. The risk of VaD according to midlife smoking status. Values are HRs from Cox pro-
portional hazards model adjusted for age (as time scale), sex, education, race, marital status, 
hypertension, high cholesterol level, BMI, diabetes, heart disease, stroke, and alcohol drinking.
5.3.6 Sensitivity analyses by stroke status 
Stroke was both highly associated with smoking (χ2 test, p < 0.001) and dementia risk (p < 0.001), 
although it did not significantly interact with how smoking affected the risk of dementia, AD, 
or VaD (p > 0.05 for all interaction term models of smoking times stroke on risk). Although 
stroke (whether intercurrent or during follow-up) did not confound or attenuate the association 
between smoking and dementia risk, the association between smoking and dementia risk was 
examined separately for those with and without a stroke because stroke is a robust predic-
tor of dementia and is highly associated with smoking. In these analyses, heavy smoking in 
midlife was shown to double the later risk for dementia, AD, and VaD even in those who had 
not suffered a stroke or who were without an intercurrent stroke (Table 10). However, these 
post-hoc subgroup analyses need to be interpreted with caution, since there were no statisti-
cally significant interaction terms of stroke times smoking on dementia risk.
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Table 10. Cox proportional hazard models of smoking and dementia risk stratified by stroke sta-
tus and intercurrent stroke status
Dementia
Hazard ratio (95 % 
confidence interval)
Dementia
Hazard ratio (95 % 
confidence interval)
Among those without 
a strokea:
Among those without 
an intercurrent 
strokeb:
Never 1.0 Never 1.0
Former 1.01 (0.94-1.1) Former 0.99 (0.93-1.06)
< 0.5 pack/day 0.97 (0.81-1.16) < 0.5 pack/day 1.07 (0.94-1.23)
0.5-1 pack/day 1.38 (1.2-1.57) 0.5-1 pack/day 1.32 (1.19-1.47)
1-2 packs/day 1.44 (1.23-1.69) 1-2 packs/day 1.35 (1.19-1.54)
≥ 2 packs/day 2.19 (1.61-2.97) ≥ 2 packs/day 1.99 (1.54-2.59)
Among those with a 
strokea:
Among those with an 
intercurrent strokeb:
Never 1.0 Never 1.0
Former 0.93 (0.85-1.03) Former 0.89 (0.68-1.17)
< 0.5 pack/day 1.29 (1.05-1.57) < 0.5 pack/day 1.33 (0.72-2.47)
0.5-1 pack/day 1.22 (1.04-1.42) 0.5-1 pack/day 1.24 (0.85-1.82)
1-2 packs/day 1.26 (1.03-1.53) 1-2 packs/day 1.33 (0.84-2.1)
≥ 2 packs/day 1.83 (1.18-2.81) ≥ 2 packs/day 1.77 (0.72-4.37)
          astroke between 1994 and 2008, never smokers as a reference group
          bstroke between 1978 and 1993, never smokers as a reference group
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5.4 PULMONARY DISEASES AND COGNITIVE IMPAIRMENT IN 
CAIDE (STUDY III)
5.4.1 characteristics of the study population according to cognitive status 
The sociodemographic and clinical characteristics of the study population according to cogni-
tive status are shown in Table 11. 
 
Table 11. Sociodemographic and clinical characteristics of the participants according to cognitive 
status in study III
All
(N=1511)
Control 
(N=1222)
Cognitive 
impairment
(N=289)
p-value
Follow-up time, years* (N=1511) 25.5 (6.2) 25.8 (6.2) 24.4 (5.9) p=0.001
Age, years*
- at baseline (N=1510)
- at 1st re-examination (N=1511)
- at 2nd re-examination (N=893)
50.3 (6.0)
71.2 (4.0)
78.6 (3.7)
50.0 (6.0)
70.9 (3.9)
78.3 (3.6)
51.5 (5.9)
72.2 (4.1)
79.5 (3.8)
p=0.000
p=0.000
p=0.000
Sex, n (%) (N=1511)
- Men
- Women
569 (37.7)
942 (62.3)
455 (37.2)
767 (62.8)
114 (39.4)
175 (60.6)
p=0.49
Education, years* (N=1486) 8.6 (3.4) 8.9 (3.5) 7.5 (2.8) p=0.000
Midlife smoking, n (%) (N=1478)
- Yes 1138 (77.0) 927 (77.4) 211 (75.4)
p=0.47
APOE ε4 carrier, n (%) (N=1380) 491 (35.6) 377 (33.5) 114 (45.1) p=0.000
Midlife physical activity, n (%) 
(N=1469)
- Sedentary
- Active
874 (59.5)
595 (40.5)
705 (59.2)
485 (40.8)
169 (60.6)
110 (39.4)
p=0.68
Midlife systolic blood pressure, mmHg* 144.3 (20.0) 143.5 (19.4) 147.7 (22.2) p=0.004
Midlife body mass index, kg/m2* 26.6 (3.8) 26.4 (3.8) 27.1 (3.8) p=0.004
Midlife serum cholesterol, mmol/l* 6.8 (1.2) 6.7 (1.2) 6.9 (1.2) p=0.02
Late-life vascular diseases, n (%) 
(N=1337)
- No
- Yes (1 or more)
993 (74.3)
334 (25.7)
837 (76.0)
264 (24.0)
156 (66.1)
80 (33.9)
p=0.017
COPD, n (%)
- At midlife (N=1496)
- At 1st re-examination     (N=1360)  
71 (4.7)
95 (7.0)
53 (4.4)
83 (7.5)
18 (6.3)
12 (4.9)
p=0.16
p=0.15
Asthma, n (%) 
- At midlife (N=1493)
- At 1st re-examination (N=1351)
25 (1.7)
185 (13.7)
19 (1.6)
150 (13.6)
6 (2.1)
35 (14.2)
p=0.50
p=0.79
Pulmonary diseases combined, n (%)
- At midlife (N=1494)
- At 1st re-examination (N=1351)
86 (5.8)
237 (17.5)
64 (5.3)
198 (17.9)
22 (7.8)
39 (15.9)
p=0.11
p=0.46
*Values are expressed as means (SD), and t-test was used; otherwise the χ2 test was used 
The individuals with cognitive impairment (MCI or dementia) were somewhat older and had 
a shorter follow-up time than the controls. They also had less education and were more often 
APOE ε4 carriers compared to the controls. The proportion of persons with midlife vascular risk 
factors and late-life vascular diseases was greater among the cognitively impaired subjects than 
among the controls. The prevalence of midlife asthma and COPD was higher and the prevalence 
of late-life COPD lower among the cognitively impaired individuals than among the controls, 
but differences between the groups were not statistically significant. There were no differences 
between the groups with regard to sex, midlife smoking status, or physical activity.    
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5.4.2 midlife pulmonary diseases and the risk of cognitive impairment
COPD in midlife increased the later-life risk of cognitive impairment even in the fully adjusted 
model (model 3, HR 1.85, 95% CI 1.05 – 3.28, Table 12). The risk increase related to midlife 
asthma was significant in the crude model (HR 2.40, 95% CI 1.07 – 5.40), but the association 
became somewhat attenuated after controlling for the possible confounding factors (model 3, 
HR 1.88, 95% CI 0.77 – 4.63). When examining those subjects with both pulmonary diseases 
combined, the risk of later impaired cognition was doubled as compared with persons without 
these pulmonary diseases (model 3, HR 1.94, 95% CI 1.16 – 3.27). 
In order to include also the non-participants the analyses were repeated in the entire study 
cohort (n=2000). In these analyses, the presence of midlife asthma also doubled the risk of later 
cognitive impairment (HR 2.09, 95% CI 1.15 – 3.80). However, adjusting for the sociodemo-
graphic and midlife covariates again attenuated the association (final model, HR 1.43, 95% CI 
0.78 – 2.61). The risk increase related to midlife COPD (final model, HR 1.27, 95% CI 0.88 – 1.84) 
and pulmonary diseases combined (final model, HR 1.33, 95% CI 0.95 – 1.85) were almost the 
same, and statistically insignificant.  
5.4.3 late-life pulmonary diseases and the risk of cognitive impairment
Next the association was examined between these pulmonary diseases diagnosed in late-life, 
i.e. after the midlife visit but prior to the first re-examination, and incidence of cognitive im-
pairment at the second re-examination. Interestingly, with regard to the late-life pulmonary 
diseases the results were opposite to those found for the midlife pulmonary diseases. Self-
reported COPD (model 3, HR 0.30, 95% CI 0.08 – 1.24) or asthma (model 3, HR 0.46, 95% CI 0.18 
– 1.17) in late-life tended to be inversely associated with the later risk of cognitive impairment, 
but the associations were not statistically significant (Table 12). However, when analysing 
both of these pulmonary diseases combined, it was found that they were associated with a 
decreased risk of subsequent cognitive impairment compared to the individuals without these 
diseases, even in the fully adjusted model (model 3, HR 0.42, 95% CI 0.19 – 0.93).
Table 12. Midlife and late-life pulmonary diseases (COPD, asthma and both combined) and the 
subsequent risk of cognitive impairment (MCI or dementia)
Hazard Ratio (95% Confidence Interval)
MIDLIFE LATE-LIFE
COPD Asthma Both 
combined
COPD Asthma Both 
combined
CRUDE 1.75 
(1.09-2.83)
2.40 
(1.07-5.40)
1.90 
(1.23-2.94)
0.41 
(0.13-1.29)
0.49 
(0.21-1.12)
0.45 
(0.22-0.92)
MODEL 1 1.44 
(0.88-2.35)
1.48 
(0.66-3.36)
1.57 
(1.00-2.46)
0.39 
(0.12-1.22)
0.49 
(0.21-1.12)
0.42 
(0.20-0.87)
MODEL 2 1.31 
(0.78-2.21)
1.49 
(0.66-3.38)
1.46 
(0.91-2.34)
0.39 
(0.12-1.22)
0.47 
(0.20-1.08)
0.41 
(0.20-0.85)
MODEL 3 1.85 
(1.05-3.28)
1.88 
(0.77-4.63)
1.94 
(1.16-3.27)
0.30 
(0.08-1.24)
0.46 
(0.18-1.17)
0.42 
(0.19-0.93)
Model 1 adjusted for age, sex, education
Model 2 adjusted additionally for midlife smoking
Model 3 adjusted additionally for APOE, midlife physical activity, systolic blood pressure, body mass in-
dex, and total serum cholesterol, and late-life vascular diseases
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5.5 HEART DISEASES AND DEMENTIA IN CAIDE (STUDY IV)
5.5.1 characteristics of the study population according to late-life heart disease status
Sociodemographic and clinical characteristics of the population in study IV according to late-
life heart disease status are shown in Table 13. The persons with any heart disease (AF, HF, 
or CHD) diagnosed prior to the first re-examination were older, had less education, and a 
shorter follow-up time than the persons without these heart diseases. The majority of the sub-
jects without heart diseases were female. As expected, the individuals diagnosed with these 
heart conditions had higher systolic blood pressure, a total serum cholesterol level, and BMI 
at midlife, and they also had more late-life diabetes and stroke than the healthy persons. In 
addition, the proportion of demented persons in both the first and the second re-examination 
was greater among the heart disease group than in the reference group. There were no differ-
ences between the groups according to their APOE ε4 carrier status, midlife smoking status, 
and physical activity.   
5.5.2 midlife heart diseases and the risk of dementia and ad
First the association was examined between heart diseases diagnosed in midlife and the sub-
sequent risk of dementia and AD at late-life. These analyses showed (model 4) that midlife AF 
(HR 0.95, 95% CI 0.12 – 7.50), HF (HR 0.84, 95% CI 0.33 – 2.13), CHD (HR 0.80, 95% CI 0.38 – 1.67), 
or all heart diseases combined (HR 0.57, 95% CI 0.27 – 1.19) were not associated with a later risk 
of dementia in the unstratified analyses. The results were similar when investigating the risk 
of AD (model 4, for AF HR 1.11, 95% CI 0.14 – 8.65, for HF HR 1.11, 95% CI 0.43 – 2.81, for CHD 
HR 1.10, 95% CI 0.52 – 2.33, all heart diseases combined HR 0.78, 95% CI 0.37 – 1.63). However, 
when the analyses were stratified according to the APOE ε4 carrier status, the individuals 
who were both APOE ε4 carriers and also had a diagnosis of HF in midlife had an increased 
risk of both dementia (model 1, HR 2.98, 95% CI 1.05 – 8.50) and AD (model 1, HR 3.44, 95% CI 
1.19 – 9.90) later in life. The association became somewhat attenuated after all adjustments for 
dementia (HR 2.70, 95% CI 0.90 – 8.13) but not for AD (HR 3.24, 95% CI 1.07 – 9.84). With respect 
to the other heart diseases or the APO ε4 non-carriers, there was no association to dementia 
or AD in these APOE-stratified analyses.   
The main analyses were repeated of the association between midlife heart diseases and 
dementia among the entire cohort including also data regarding the non-participants from 
the registries (adjusted for sociodemographic and midlife vascular factors). These analyses 
produced comparable results.
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Table 13. Sociodemographic and clinical characteristics of the participants according to late-life 
heart disease status in study IV 
All
(N=1510)
No heart 
diseases prior to 
1st follow-up
(N=997)
All heart 
diseases prior 
to 1st follow-up 
combined
(N=513)
p-value
Follow-up time, years* (N=1510) 25.5 (6.3) 25.9 (6.2) 24.6 (6.2) 0.000
Age, years*
-at baseline (N=1510)
-at 1st re-examination (N=1414)
-at 2nd re-examination (N=896)
50.3 (6.0)
71.3 (4.0)
78.6 (3.7)
49.9 (6.0)
70.9 (3.9)
78.4 (3.6)
51.1 (5.9)
71.9 (4.0)
79.0 (3.8)
0.000
0.000
0.03
Sex, N (%) (N=1510)
-Men
-Women
568 (37.6)
942 (62.4)
340 (34.1)
657 (65.9)
228 (44.4)
285 (55.6)
0.000
Education, years* (N=1485) 8.6 (3.4) 8.9 (3.4) 8.1 (3.3) 0.000
Midlife systolic blood pressure, mmHg* 
(N=1510)
144.3 (20.0) 143.1 (19.2) 146.6 (21.3) 0.002
Midlife total cholesterol, mmol/l* 
(N=1510)
6.8 (1.2) 6.6 (1.2) 7.0 (1.2) 0.000
Midlife body mass index, kg/m2* (N=1510) 26.6 (3.8) 26.2 (3.7) 27.3 (3.8) 0.000
APOE ε4 carrier, 
N (%) (N=1379)
491 (35.6) 310 (35.2) 181 (36.3) 0.70
Midlife smoking, 
N (%) (N=1477)
-Yes 340 (23.0) 221 (22.6) 119 (23.9)
0.55
Physical activity, N (%) (N=1468)
-Sedentary
-Active
874 (59.5)
594 (40.5)
586 (60.2)
388 (39.8)
288 (58.3)
206 (41.7)
0.49
Late-life diabetes, 
N (%) (N=1371)
147 (10.7) 55 (6.3) 92 (18.4) 0.000
Late-life stroke, 
N (%) (N=1373)
99 (7.2) 41 (4.7) 58 (11.7) 0.000
Dementia at 1st or 2nd re-examination, N 
(%) (N=1510)
127 (8.4) 72 (7.2) 55 (10.7) 0.02
Dementia at 2nd re-examination N (%), 
(N=738)
46 (6.2) 25 (5.0) 21 (9.0) 0.03
Alzheimer’s disease at 1st or 2nd re-exami-
nation, N (%) (N=1484)
101 (6.8) 56 (5.7) 45 (8.9) 0.02
Alzheimer’s disease at 2nd re-examination, 
N (%), (N=732)
40 (5.5) 22 (4.4) 18 (7.8) 0.06
*Values are expressed as means (SD), and t-test was used; otherwise the χ2 test was used
5.5.3 late-life heart diseases and the risk of dementia
Next the association between late-life heart diseases, i.e. diagnosed prior to the first re-exam-
ination, and incident dementia at the second re-examination was investigated. The results are 
presented in Table 14. These analyses revealed that those subjects with an AF diagnosis prior 
to the first re-examination had an over two-fold risk of developing dementia later in life com-
pared to persons without AF even after all adjustments. There was also a non-significant trend 
towards an increased risk of subsequent dementia regarding late-life HF. CHD diagnosed prior 
to the first re-examination did not increase the later risk of dementia. However, the individuals 
with at least one of these heart diseases at late-life had an almost two-fold risk of subsequent 
dementia compared to those without these heart diseases. 
Analyses without the imputed data including only the subjects with no missing informa-
tion on the covariates produced somewhat stronger results (model 4, for AF HR 3.03, 95% CI 
1.20 – 7.65, for HF HR 3.86, 95% CI 1.47 – 10.11, for CHD HR 2.24, 95% CI 1.12 – 4.49, and for all 
heart diseases combined HR 2.84, 95% CI 1.43 – 5.64).
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Table 14. Heart diseases at late-life and the subsequent risk of dementia and AD
Hazard Ratio (95% Confidence Interval)
Atrial fibrillation Heart failure Coronary heart 
disease
All combined
DEMENTIA
Model 1 2.32 (0.98 – 5.52) 1.89 (0.95 – 3.75) 1.43 (0.77 – 2.66) 1.65 (0.91 – 2.97)
Model 2 2.37 (0.99 – 5.68) 1.92 (0.94 – 3.90) 1.56 (0.83 – 2.94) 1.74 (0.95 – 3.18)
Model 3 2.18 (0.89 – 5.31) 1.79 (0.87 – 3.67) 1.53 (0.81 – 2.90) 1.71 (0.93 – 3.14)
Model 4 2.61 (1.05 – 6.47) 2.06 (1.00 – 4.27) 1.66 (0.87 – 3.16) 1.94 (1.04 – 3.62)
ALZHEIMER’S DISEASE
Model 1 2.68 (1.12 – 6.44) 1.99 (0.96 – 4.10) 1.33 (0.68 – 2.60) 1.64 (0.87 – 3.08)
Model 2 2.66 (1.10 – 6.42) 2.03 (0.96 – 4.27) 1.47 (0.74 – 2.91) 1.75 (0.92 – 3.32)
Model 3 2.53 (1.05 – 6.12) 1.84 (0.87 – 3.89) 1.39 (0.70 – 2.76) 1.68 (0.88 – 3.22) 
Model 4 2.54 (1.04 – 6.16) 1.82 (0.84 – 3.97) 1.38 (0.69 – 2.77) 1.68 (0.86 – 3.26)
Model 1 adjusted for sex and education
Model 2 adjusted additionally for midlife systolic blood pressure, cholesterol, and body mass index 
Model 3 adjusted additionally for APOE, midlife smoking, and physical activity 
Model 4 adjusted additionally for diabetes or impaired glucose tolerance and stroke at late-life
In the analyses of the entire cohort including also the non-participants (adjusted for sociode-
mographic and midlife vascular factors), the association between late-life AF (HR 1.21, 95% CI 
0.73 – 2.01), HF (HR 1.36, 95% CI 0.98 – 1.89), CHD (HR 1.20, 95% CI 0.91 – 1.58), and all heart 
diseases combined (HR 1.16, 95% CI 0.90 – 1.51) and the risk of subsequent dementia was 
somewhat attenuated.
5.5.4 late-life heart diseases and the risk of ad
We also investigated late-life heart diseases in regard to subsequent risk of AD later in life. The 
subjects with AF prior to the first re-examination had an over two-fold risk of developing also 
AD at late-life compared to those without AF (Table 14). Regarding late-life HF and all heart 
diseases combined, there was a non-significant trend for an increased risk of AD later in life. 
Late-life CHD was not associated with a risk of AD.
5.5.5 Late-life heart diseases, APOE ε4 and the risk of dementia and AD 
Finally it was decided to investigate whether the APOE ε4 carrier status could modify the as-
sociation between late-life heart diseases and dementia risk. These APOE stratified analyses 
revealed that the APOE ε4 non-carriers with a AF diagnosis prior to the first re-examination 
had an over three-fold risk of developing subsequent dementia and six-fold risk of develop-
ing AD later in life compared to the APOE ε4 non-carriers without AF (Tables 15 and 16). The 
APOE ε4 non-carriers with late-life HF were also at an increased risk of AD, but the risk of 
dementia became attenuated after all adjustments. In the consideration of all these late-life 
heart diseases combined there was a trend for an increased risk of both dementia and AD 
later in life among the APOE ε4 non-carriers. With respect to the APOE ε4 carriers, there were 
no significant associations found between late-life heart diseases and the risk of developing 
subsequent dementia or AD.
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Table 15. Heart diseases at late-life and the risk of dementia, APOE ε4 stratified analyses
Hazard Ratio (95% Confidence Interval)
Atrial fibrillation Heart failure Coronary heart 
disease
All combined
APOE ε4-
Model 1 4.19 (1.35 – 13.02) 3.17 (1.18 – 8.47) 1.65 (0.64 – 4.25) 2.93 (1.16 – 7.43)
Model 2 4.36 (1.37 – 13.84) 3.11 (1.11 – 8.72) 1.85 (0.70 – 4.90) 3.09 (1.19 – 8.01)
Model 3 4.06 (1.28 – 12.93) 2.28 (0.77 – 6.74) 1.82 (0.67 – 4.93) 2.83 (1.07 – 7.49 )
Model 4 3.76 (1.15 – 12.34) 1.96 (0.62 – 6.21) 1.68 (0.61 – 4.61) 2.63 (0.94 – 7.36)
APOE ε4+
Model 1 1.42 (0.32 – 6.25) 1.33 (0.49 – 3.59) 1.62 (0.70 – 3.75) 1.44 (0.63 – 3.28)
Model 2 1.37 (0.31 – 6.06) 1.27 (0.46 – 3.53) 1.64 (0.70 – 3.83) 1.40 (0.61 – 3.25)
Model 3 1.39 (0.31 – 6.19) 1.17 (0.41 – 3.34) 1.58 (0.67 – 3.74) 1.34 (0.57 – 3.16) 
Model 4 1.42 (0.32 – 6.36) 1.24 (0.42 – 3.64) 1.68 (0.68 – 4.14) 1.40 (0.58 – 3.39)
Model 1 adjusted for sex and education
Model 2 adjusted additionally for midlife systolic blood pressure, cholesterol, and body mass index 
Model 3 adjusted additionally for midlife smoking and physical activity 
Model 4 adjusted additionally for diabetes or impaired glucose tolerance and stroke at late-life
Table 16. Heart diseases at late-life and the risk of AD, APOE ε4 stratified analyses
Hazard Ratio (95% Confidence Interval)
Atrial fibrillation Heart failure Coronary heart 
disease
All combined
APOE ε4-
Model 1 6.38 (1.93 – 21.04) 4.01 (1.31 – 12.27) 1.18 (0.37 – 3.82) 3.00 (1.01 – 8.84)
Model 2 6.52 (1.91 – 22.28) 4.26 (1.32 – 13.74) 1.38 (0.42 – 4.56) 3.31 (1.09 – 10.02)
Model 3 6.49 (1.87 – 22.54) 3.69 (1.09 – 12.54) 1.36 (0.40 – 4.61) 3.21 (1.04 – 9.96)
Model 4 6.05 (1.75 – 20.93) 3.69 (0.99 – 13.68) 1.20 (0.35 – 4.17) 3.01 (0.93 – 9.75)
APOE ε4+
Model 1 1.42 (0.32 – 6.25) 1.33 (0.49 – 3.59) 1.62 (0.70 – 3.75) 1.44 (0.63 – 3.28)
Model 2 1.37 (0.31 – 6.06) 1.27 (0.46 – 3.53) 1.64 (0.70 – 3.83) 1.40 (0.61 – 3.25)
Model 3 1.39 (0.31 – 6.19) 1.17 (0.41 – 3.34) 1.58 (0.67 – 3.74) 1.34 (0.57 – 3.16)
Model 4 1.42 (0.32 – 6.36) 1.24 (0.42 – 3.64) 1.68 (0.68 – 4.14) 1.40 (0.58 – 3.39)
Model 1 adjusted for sex and education
Model 2 adjusted additionally for midlife systolic blood pressure, cholesterol, and body mass index 
Model 3 adjusted additionally for midlife smoking and physical activity 
Model 4 adjusted additionally for diabetes or impaired glucose tolerance and stroke at late-life
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6 Discussion
6.1 SMOKING AND DEMENTIA
The current project investigated the relation between midlife smoking and the risk of late-life 
dementia in two separate, large, population-based studies. The first study which was carried 
out in a population of Finnish men and women showed that midlife smoking is associated with 
an increased risk of both dementia and AD after an average follow-up of 21 years; however, 
this effect was seen only among the APOE ε4 carriers. The second study was carried out in a 
large, multiethnic cohort of health plan members living in the United States and found that 
midlife smoking doubled the risk of dementia, as well as the subtypes AD and VaD, after 23 
years follow-up; furthermore, the risk was dose dependent i.e. the risk increased with increas-
ing amount of smoked cigarettes, and those who reported smoking more than 2 packs per day 
in middle age were at the greatest risk of suffering dementia in late-life.
A recent meta-analysis of 19 prospective studies, with at least 12 months of follow-up, also 
indicates that current smokers have almost two-fold risk of developing dementia, AD, and VaD 
compared to non-smoking persons (Anstey et al. 2007). On the contrary, previously several 
case-control studies have suggested that smoking may even be protective of dementia (Graves 
et al. 1991, Lee 1994, Van Duijn et al. 1994). This was speculated to be biologically plausible 
because of the neuroprotective effects of nicotine; the predominant component of cigarette 
smoke. For example, nicotine has been shown to protect neurons from excitotoxic or ischemic 
cell death under certain circumstances in rat cortical neurons (Shimohama et al. 1998, Akaike 
et al. 1994), and to be antiamyloidogenic via inhibiting Aβ formation and by breaking down 
already preformed Aβ (Zeng et al. 2001, Ono et al. 2002). Furthermore, nicotine may counter-
balance the impairment of cholinergic neurotransmitter system present in AD by causing up-
regulation of nicotinic cholinergic receptors in the brain (Benwell et al. 1988). This concept is 
supported by studies carried out with experimental animals as well as with AD patients which 
have revealed that nicotine can improve performance in cognitive tasks (Levin et al. 1998, 
Rusted et al. 2000). However, in addition to nicotine, cigarette smoke contains a plethora of 
harmful compounds (chemicals, heavy metals, free radicals), and smoking is known to predis-
pose to many diseases including cardiovascular and cerebrovascular disease, stroke, and pul-
monary diseases (especially COPD) (Bartecchi et al. 1994, Shinton et al. 1989). The association 
of cigarette smoking with blood vessel wall damage including endothelial injury is postulated 
to be an important mechanism behind the increased risk of atherosclerotic diseases related to 
smoking (Michael Pittilo 2000). Smoking also evokes oxidative stress and promotes inflamma-
tion in the body, thereby exacerbating mechanisms which are thought to be important in the 
development of AD as well (Markesbery 1997, Akiyama et al. 2000). Increased oxidative stress 
through several mechanisms is evident in AD, and may cause neuronal degeneration; Aβ may 
also contribute to this oxidative damage through the generation of free radicals. Smokers may 
experience more oxidative stress than non-smokers; cigarette smoke contains free radicals and 
it affects the inflammatory-immune systems, which then activate phagocytes that generate 
further oxidative damage (Traber et al. 2000). Furthermore, smokers lymphocytes are shown 
to exhibit more mistakes in the repair of DNA damage than cells from non-smokers, implying 
that smokers may have impaired cell repair mechanisms as compared to non-smokers, and 
consequently they may be more prone to suffer neurodegeneration (Au et al. 1991). The lower 
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cerebral blood flow of smokers compared to non-smokers detectable in single-photon emission 
computed tomography (SPECT) may also cause further neuronal damage (Siennicki-Lantz et 
al. 2008). Indeed, smoking is known to be associated with both reduced cortical gray matter 
density in brain regions associated with incipient AD (Almeida et al. 2008) and reduced micro-
structural integrity of cerebral white matter in MRI (Gons et al. 2011). When one considers all 
these negative effects of smoking on brain health, one should not be surprised that smoking 
would be deleterious to the brain, rather than protective against neurodegenerative diseases 
such as AD. 
In recent years, evidence from several cohort studies has accumulated to propose that, in 
contrast to the results of the earlier case-control studies, smoking actually increases the risk 
of dementia and AD (Ott et al. 1998, Launer et al. 1999, Merchant et al. 1999, Tyas et al. 2003, 
Moffat et al. 2004, Juan et al. 2004, Luchsinger et al. 2005, Aggarwal et al. 2006, Reitz et al. 2007, 
Chen et al. 2011, Ronnemaa et al. 2011, Kimm et al. 2011). The present results are in concord-
ance with these findings. However, there are also prospective studies which have detected no 
association between smoking and dementia risk (Hebert et al. 1992, Yoshitake et al. 1995, Broe 
et al. 1998, Brayne et al. 1998, Wang et al. 1999, Doll et al. 2000, Lindsay et al. 2002, Peters et al. 
2009a). The previous case-control studies indicating an inverse relationship between smok-
ing and dementia were probably biased by selective survival, as dementia and smoking both 
increase mortality and the individuals who smoke and become demented are thereby under-
represented in elderly cohorts (Riggs 1993). The more recent prospective cohort studies have 
also been conducted mainly in elderly cohorts with relative short follow-up times (2 to 7 years), 
and thus there might be some bias inherent in these studies as well, especially regarding se-
lective survival and also possible preclinical dementia in the control subjects (Hernan et al. 
2008). When investigating risk factors for a disease with a long preclinical phase, such as AD, 
it is essential to start the assessment before the neuropathology has significantly progressed 
in the brain, if one wishes to be able to investigate the factors specifically as a true long-term 
“risk factors”, rather than a “risk predictors”, for the disease. However, thus far, only three 
previous cohort studies have investigated the effect of smoking specifically in midlife on the 
risk of late-life dementia, and these have produced somewhat inconclusive results (Tyas et al. 
2003, Ronnemaa et al. 2011, Kimm et al. 2011). In this respect, this present project substantially 
adds to the current knowledge about this matter.
The first study of the current thesis is the first in which the increased risk of dementia and 
AD associated with smoking was detected only among the APOE ε4 carriers whereas there 
was no increased risk detected among the non-carriers. There are some previous cohort studies 
suggesting the opposite, i.e. especially the APOE ε4 non-carriers who smoke are at an increased 
risk of having dementia while the smoking APOE ε4 carriers do not have an increased disease 
risk (Ott et al. 1998, Aggarwal et al. 2006, Reitz et al. 2007, Ronnemaa et al. 2011). In one study 
the APOE carrier status only slightly modified the association between smoking and dementia 
(Merchant et al. 1999). Furthermore, in one study which focused specifically on midlife smok-
ing, the APOE status did not modify the relationship between pack-years of smoking and the 
risk of AD later in life (Tyas et al. 2003). However, the APOEε4 carrier status of the participants 
has been taken into account in only a few of the previous studies investigating the association 
between smoking and dementia; thus, since data are scarce it is difficult to draw any definite 
conclusions on the direction of this interaction on the disease risk. It has been speculated 
that those persons who are genetically susceptible to AD could benefit from smoking via 
stimulation of the impaired cholinergic system by the nicotine present in the cigarette smoke. 
However, it has also been postulated that the APOE ε4 carriers would be more vulnerable than 
61
the non-carriers to various lifestyle related risk factors for AD (e.g. alcohol drinking, physical 
inactivity, and dietary fat intake), and the increase in dementia risk related to these factors is 
particularly high among the ε4 carriers (Kivipelto et al. 2008). Bearing in mind the harmful 
effects of smoking, it is really not surprising if this habit also were to increase the disease 
risk, in particular in already genetically susceptible persons. The mixed findings regarding 
the interaction between smoking and APOE on dementia risk in previous studies may be due 
to many factors. Firstly, it has been proposed that the effect of APOE ε4 allele on the risk of 
AD may attenuate with increasing age (Farrer et al. 1997). Moreover, both smoking (de Groot 
et al. 2004) and the APOE ε4 allele (Ewbank 2004) are known to increase mortality. Thus, the 
APOE ε4 carriers who survive until old age may possess some other factors protecting them 
not only from death, but also from dementia, and these factors may counterbalance the disease 
risk resulting from smoking. So, at least some effect of selective survival cannot be excluded 
in studies investigating this gene-environment interaction, especially in using elderly cohorts. 
Previous studies assessing this matter have been mainly conducted on elderly cohorts (+65 
years) and the follow-up times have been relatively short (mean 2 to 7 years), with the exception 
of one report from the HAAS (Tyas et al. 2003). Another factor that can at least partially explain 
these disparate findings is the fact that in Finland and Scandinavia the proportion of APOE ε4 
carriers in the population is known to be somewhat greater (in the present CAIDE study 35 %) 
than in some other European countries (on average 15 %) (Schiele et al. 2000). While the inde-
pendent effect of the APOE ε4 allele on dementia risk (after controlling for sociodemographic 
and vascular factors OR 2.83, 95% CI 1.61-4.97) (Kivipelto et al. 2008) in this cohort is similar to 
that in other studies (Farrer et al. 1997), it is possible that also due to the higher proportion of 
APOE ε4 carriers examined here the effects related to this genotype are more easily detectable 
here than in a cohort with less APOE ε4 carriers. It would have been extremely interesting to 
study this interaction also in the second study of the current project with a larger, multiethnic 
population but, unfortunately, information on their APOE ε4 carrier status was not available.
The amount of smoking and the subsequent risk of dementia were evaluated in both current 
studies. In the first study the concept of pack-years was utilized. Information on pack-years 
could be calculated for 69.8 % of the current smokers. There was a non-significant trend to-
wards an increased risk of both dementia and AD with having smoked at least 20 pack-years, 
but the association did not reach statistical significance, probably due to the compromised sta-
tistical power in these analyses. In the second study with a larger study sample, it was possible 
to evaluate this matter further by dividing the current smokers into categories according to the 
amount of cigarettes smoked in midlife. Interestingly, a dramatic increase in the incidence of 
dementia, AD, and VaD was found for those heavy smoking individuals who reported smok-
ing more than 2 packs per day at midlife. Former smoking or smoking less than 0.5 a pack per 
day in midlife was not associated with any later dementia risk. Only a few previous studies 
have considered the amount of smoked cigarettes while assessing the risk of dementia attribut-
able to smoking. The results from the second study are in concordance with the studies which 
indicate that heavy smoking increases the risk of dementia more than smoking fewer cigarettes 
(Ott et al. 1998, Tyas et al. 2003, Juan et al. 2004, Reitz et al. 2007). There is also another study 
in addition to the first study which did not find any association between pack-years and the 
risk of AD among current smokers (Aggarwal et al. 2006).
One mediating factor between smoking and dementia risk could be stroke, as smoking is a 
robust risk factor for stroke (Shinton et al. 1989) which in turn increases the risk of dementia, 
especially VaD (Mackowiak-Cordoliani et al. 2005). In the first study the analyses were ad-
justed for stroke but adding stroke as a covariant to the model did not attenuate the association 
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between smoking and dementia or AD. In the second study, heavy smoking in midlife was 
shown to double the later risk for dementia, AD, and VaD even among those without a stroke 
or without an intercurrent stroke. Thus, the association between smoking and increased risk 
of dementia seems to be independent from stroke.
The strengths of the first study in the current thesis are the large population-based study 
design, including both sexes, and the long follow-up time of the cohort. The diagnostic pro-
tocol of CAIDE study is exhaustive; consequently, the diagnoses made in the study can be 
considered as reliable. Moreover, due to the fact that the putative risk factors were assessed 
at midlife it is unlikely that subclinical dementia would have affected the subjects’ smoking 
habits and subsequently on the results. Only in the analyses regarding quitting smoking could 
reverse causality or recall bias have played a role and therefore these results should be inter-
preted with caution. There are also some limitations regarding the first study that have to be 
discussed. Firstly, as the CAIDE study was undertaken in those who participated in the midlife 
examination and survived until the re-examination in late-life, the results can be considered 
as being applicable only among those middle-aged persons who survive for the next 20 years. 
Information about those individuals who had died prior to the first re-examination was not 
available at the time of this study, and therefore, the possibility of survival bias must be taken 
into consideration when interpreting the results. However, as previously stated, both the APOE 
ε4 carrier status (Ewbank 2004) and smoking (de Groot et al. 2004) have been shown to be as-
sociated with increased mortality. Accordingly, if it is assumed that among the deceased there 
were more APOE ε4 carriers, and that they were more likely to be demented as well, then the 
results would not overestimate but rather underestimate the true effects of smoking on the risk 
of dementia and AD later in life. Secondly, a possible bias could exist due to non-participation 
in the re-examination, but this is unlikely to have occurred because repeating the analyses 
among the whole study sample including also the non-participants did not change the results. 
Third, despite the relatively large cohort in the current study, the sample size was still not large 
enough in some of the analyses for the subgroups (especially for example the assessment of the 
impact of pack-years), potentially resulting in compromised statistical power and subsequently 
a failure to detect true associations in these analyses. One further possible limitation to be 
considered is the reliability of the self-reported data. However, if some misreporting regarding 
information about smoking habits has occurred, one would expect that it would more likely 
relate to the amount of smoking rather than the smoking status itself, and furthermore, occur 
independently of the APOE ε4 carrier status of the person; thus, ranking of individuals into 
different smoking categories, as conducted here, should be possible.
The second study of the present thesis is the first attempt to investigate the long-term as-
sociation between smoking amount in midlife and the subsequent risk of dementia and sub-
types AD and VaD later in life in a large multiethnic cohort. In this study, midlife smoking 
was associated with an increased risk of both AD and VaD. The relationship between smoking 
and VaD has not been as widely investigated as its relationship with AD. Smoking is a well 
established risk factor for stroke (Gorelick et al. 1999), and consequently, it can also predispose 
to multi-infarct dementia. Interestingly, in the current study, the association between smoking 
and VaD remained significant even after controlling for various potential vascular confound-
ing factors (including stroke), thus, smoking seems to also have some independent effect on 
VaD, beyond its acceleration of cerebrovascular disease. It is possible that smoking can affect 
the development of dementia via both vascular and neurodegenerative pathways. Moreover, 
the availability to access to this large and diverse cohort with several ethnic groups, as well as 
both sexes, meant that one could investigate the interaction between smoking and race as well 
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as smoking and sex on the disease risk although no interactions were actually found. This is an 
important finding, because, despite the fact that the incidence of dementia is believed to vary 
by race (Gurland et al. 1999) previous studies of putative risk factors for dementia have mainly 
been conducted within Caucasian cohorts. The results of the second study are generalizable to 
elderly populations at risk for dementia. Based on these results, it is possible to postulate that 
the deleterious effects of smoking on dementia risk seem to be the same for both genders and 
across different ethnic groups.
One limitation of the second study is the definition of how dementia was diagnosed since 
this was obtained from medical records. Although the diagnoses were not systematically and 
clinically determined according to a strict study protocol, the dementia subtypes (AD and VaD) 
had been diagnosed by a neurologist or neuropsychologist in a memory clinic according to 
common clinical practice. The diagnoses of VaD in this study refer to multi-infarct dementia 
the diagnosis of which is more straightforward than that of AD or mixed dementia. Therefore, 
the diagnosis of VaD may be considered as quite reliable, while the AD group may also have 
included subjects with mixed dementia, as AD is more likely to be diagnosed in a person hav-
ing memory impairment as a leading symptom. Furthermore, there might be some subjects 
with undiagnosed dementia in the cohort, and in addition, some AD and VaD cases might 
have been missed in the participants who died prior to the onset of the assessment in 1994. 
Thus, some selective survival effect cannot be ruled out with regard to the current results. 
Nonetheless, if one assumes that among the deceased there were more smokers, and that the 
deceased were also more likely to be demented, then the current results would not overesti-
mate but rather underestimate the true effects of smoking on the risk of dementia later in life. 
Another limitation is that the smoking data were collected at midlife only, thus it was not pos-
sible to evaluate the effect of quitting smoking on dementia risk in this cohort. Unfortunately 
information on the APOE ε4 carrier status was not available for this cohort, and therefore it 
was not possible to ascertain the interaction between smoking and APOE ε4 carrier status on 
the disease risk.
6.2 PULMONARY DISEASES AND COGNITIVE IMPAIRMENT
The third study examined the association between midlife and late-life self-reported chronic 
obstructive pulmonary disease (COPD) and asthma and the lifelong risk of cognitive impair-
ment (MCI and dementia) in the CAIDE population. In this study, midlife COPD and asthma 
were associated with an almost two-fold risk of cognitive impairment after an average of 25 
years’ follow-up. Adjusting for various midlife and late-life sociodemographic factors, APOE, 
and vascular risk factors and diseases somewhat attenuated the association between midlife 
asthma and cognitive impairment, but the results regarding COPD remained unchanged even 
after full adjustments. The results of the analyses with the combined pulmonary disease vari-
able were also comparable; the individuals having either one of these pulmonary diseases 
in midlife exhibited a two-fold risk of suffering cognitive impairment later in life compared 
to those without these pulmonary diseases. Interestingly, pulmonary diseases diagnosed if 
not until later in life (between baseline visit and the first re-examination) seemed to show 
an inverse relationship with cognitive impairment. When analysing COPD or asthma sepa-
rately, the association was not statistically significant, but when these pulmonary diseases 
were analysed as one combined variable they were associated with a 55 % reduced risk in the 
subsequent cognitive impairment compared to persons without the diseases, and the result 
remained the same even in the fully adjusted model.
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There are several previous studies carried out during the past few decades indicating that 
persons diagnosed with COPD display cognitive impairment which has been measured with 
a variety of cognitive tests (Grant et al. 1982, Incalzi et al. 1993, Liesker et al. 2004, Ozge et al. 
2006, Klein et al. 2010, Thakur et al. 2010). However, the previous studies have been mainly 
cross-sectional and case-control studies, and instead of the actual risk of MCI or dementia, 
they have focused on the effect of COPD on various cognitive test results. There are no previ-
ous prospective studies that would have examined the effect of COPD on the actual risk of 
developing MCI or dementia during the disease course. With regard to asthma, there is only 
one previous study which examined the relationship between asthma, along with some other 
chronic atopic disorders, and dementia after a follow-up of over 22 years (Eriksson et al. 2008). 
Thus, the current study is the first to examine the lifelong effect of these common pulmonary 
diseases on the later risk of clinically diagnosed MCI and dementia, and it fills a distinct gap 
in the current knowledge of putative associations between these conditions.
While interpreting current results one must consider if there is any plausible pathophysi-
ological relation between these diseases. One would think that pulmonary diseases affect 
primarily the lungs, but on the other hand presumably one can speculate that they can cause 
cognitive impairment, i.e. dysfunction in the brain. COPD is primarily characterised by the 
presence of airflow limitations resulting from airway inflammation and remodelling often 
associated with parenchymal destruction and the development of emphysema. However, re-
cently there has been an increasing awareness of the systemic effects of COPD. A broad array 
of physical functional limitations (e.g. lower extremity functioning, exercise performance, skel-
etal muscle strength, and self-reported limitation in basic physical actions) have been found to 
be specifically attributable to COPD, indicating that COPD has an impact on many body func-
tions remote from the lung (Eisner et al. 2008). Furthermore, in many patients, the disease is as-
sociated with several systemic manifestations that can effectively result in impaired functional 
capacity, worsening dyspnoea, reduced health-related quality of life, and increased mortality. 
For example these include the presence of concomitant cardiovascular diseases, malnutrition 
involving primarily the loss and dysfunction of skeletal muscles, osteoporosis, anaemia, and 
depression. It has been proposed that increased inflammation encountered in subjects with 
COPD may be the link between COPD and other comorbidities and the systemic manifesta-
tions (Barnes et al. 2009). Chronic inflammation plays an important role also in the pathogen-
esis and expression of asthma (Chung et al. 1999). Inflammatory components are also known 
to be involved in the development of cognitive decline and dementia (Akiyama et al. 2000, 
Dziedzic 2006) and this may be one mediating factor linking these conditions. Furthermore, 
patients with COPD are also frequently smokers. Smoking, as well as acute exacerbations of 
COPD and asthma, is associated with a marked oxidant/antioxidant imbalance in the blood 
and thereby increased oxidative stress in the whole body, which in turn may exacerbate neu-
rodegeneration (Rahman et al. 1996a, Rahman et al. 1996b). 
There are some interesting studies which have observed a deterioration in neuropsycho-
logical tests in conjunction with altered cerebral perfusion in SPECT in persons diagnosed 
with COPD; hypoxemic COPD patients experience greater deteriorations in cerebral perfusion 
and cognitive performance compared to non-hypoxemic COPD patients or normal controls 
(Antonelli Incalzi et al. 2003, Ortapamuk et al. 2006). It has been postulated that the presence 
of a condition that lowers cerebral perfusion needs to be present before neurodegeneration and 
cognitive dysfunction will be expressed in AD (de la Torre 1999). Hypoperfusion ultimately 
leads to reduced delivery of oxygen and nutrients to the brain perhaps triggering dysfunction 
and death of neurons and glial cells. Moreover, one study has indicated that even mild hypox-
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emia, without any impairment of the energy supply to the brain, may impair the metabolism 
of several crucial neurotransmitters, including acetylcholine, and in that way contribute to 
dysfunction in the brain (Gibson et al. 1981). According to previous research, hypoxemia seems 
to be a major factor in development of cognitive impairment in patients with COPD. However, 
cognitive dysfunction was observed also in a study which investigated non-hypoxemic, stable 
COPD patients (Liesker et al. 2004), and thus there are probably other contributing factors. 
Asthma is associated with an increased risk of cardiovascular diseases and stroke (Iribarren 
et al. 2004, Onufrak et al. 2008) which are also known to increase the risk of dementia 
(Luchsinger et al. 2005, Newman et al. 2005, Honig et al. 2003). In addition, because of the re-
stricted lung function related to both COPD and asthma these diseases may lead to decreased 
physical activity, and also sedentary lifestyle is considered as a risk factor for dementia (Rovio 
et al. 2005). However, in the present study, the elevated risk was detected even after controlling 
for physical activity, and not only for several midlife but also for late-life cardiovascular risk 
factors and diseases. Therefore, these factors alone do not explain the increased risk of cogni-
tive impairment related to the pulmonary diseases in focus. Hypoxemia and hypoperfusion 
in the brain, increased oxidative stress, and inflammation may be some of the mechanisms 
leading to augmentation of neurodegeneration, and consequently, to cognitive dysfunction 
and dementia in patients with pulmonary diseases, although the primary disease pathology 
involves the lungs. However, the exact mechanisms behind the association remain to be clari-
fied in future studies. 
Interestingly, in the current study, pulmonary diseases not diagnosed until late-life (be-
tween baseline visit and the first re-examination) seemed to be associated with a lower risk of 
cognitive impairment later in life. There is one earlier study from Sweden which has described 
similar results i.e. indicating a reduction, although statistically non-significant, in the risk of 
AD and dementia due to asthma (Eriksson et al. 2008). However, both asthma in the elderly 
(Bellia et al. 2007) and restrictive pulmonary dysfunction at spirometry (possibly pointing to 
COPD) (Scarlata et al. 2008) are well known to increase mortality. Cognitive impairment has 
been shown to increase mortality as well (Stump et al. 2001). Thus, this apparently protective 
effect in the late-life analyses may be due to poorer survival among the cognitively impaired 
persons with pulmonary diseases thereby reflecting selective survival rather than a true pro-
tective effect of pulmonary diseases against cognitive impairment. This concept is also sup-
ported by findings from the Swedish study which indicate that individuals with a history 
of asthma have a shorter life expectancy after AD diagnosis than subjects without asthma 
(Eriksson et al. 2008). Another possible explanation for the present findings may be that as the 
pathophysiological processes leading to cognitive impairment and dementia require decades 
to develop, pulmonary diseases not diagnosed until in late-life may not have sufficient time 
to affect the risk of cognitive decline and dementia. One could argue that advances in both 
diagnoses and medical treatment of pulmonary disorders may also have resulted in the fact 
that the pulmonary diseases reported at the time of the midlife examination were more se-
vere than those reported at the time of the late-life examination. Moreover, subjects who are 
diagnosed with pulmonary diseases only later in life may have some other factors (i.e. more 
effective cell repair mechanisms) protecting them from pulmonary disease earlier; these same 
factors may protect these individuals from progressing to dementia and may counterbalance 
the increased disease risk resulting from pulmonary diseases. 
The strengths of the third study include the thorough study protocol of the CAIDE study, 
which increases the reliability of the results. One possibility for the some survival bias exists 
also regarding the third study; however, if some survival bias did exist it would probably un-
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derestimate the association between pulmonary diseases and cognitive impairment and de-
mentia, not the opposite. There might also be some bias considering the self-reported data. In 
particular, the COPD diagnoses in this study may also include some other chronic pulmonary 
diseases, probably mostly asthma. Especially among the elderly population, the distinction 
between asthma and COPD may be difficult, and individuals may also have components of 
both diseases (i.e. both obstructive and restrictive pulmonary dysfunction features). Therefore, 
analyses with the variable including both pulmonary diseases combined were also carried out 
but they produced comparable results. However, some bias due to misclassification may have 
occurred regarding the categorization to asthma and COPD.
6.3 HEART DISEASES AND DEMENTIA AND ALZHEIMER’S DISEASE
The fourth study aimed to assess the role of three common heart diseases atrial fibrillation 
(AF), heart failure (HF), and coronary heart disease (CHD) diagnosed in midlife and in late-life 
on the later risk of subsequent dementia and AD in the CAIDE population after an average 
follow-up of 25 years. In this study, AF diagnosed in late-life (prior to the first re-examina-
tion) was an independent risk factor for later dementia and AD; the risk was more than dou-
bled compared to persons without AF in late-life. Late-life HF tended to increase the risks as 
well. CHD alone at late-life was not associated with subsequent dementia or AD later in life. 
However, the presence of at least one of these heart diseases prior to the first re-examination 
increased the late-life risk of dementia; the subsequent increased risk of AD was borderline 
significant. The associations were somewhat modified by the APOE ε4 carrier status; in the 
stratified analyses, the increased risk of dementia and AD related to late-life heart diseases was 
seen only among the APOE ε4 non-carriers. The diagnosis of AF or CHD already in midlife 
did not have any effect on the risk of dementia later in life, but the APOE ε4 carriers with HF 
in middle age had an increased risk of both dementia and AD later in life. In summary, these 
results indicate that these common heart diseases, especially AF, in late-life may predispose 
the individual also to subsequent dementia. Our results also suggest that the effect of genetic 
predisposition may affect the disease risk differently at different time points in life, a matter 
which has not been previously investigated with regard to heart diseases.
Earlier cohort studies which have investigated the association between AF and dementia 
have given mixed results. Some studies have indicated an increased risk of dementia (Frishman 
et al. 1996, Rastas et al. 2007, Peters et al. 2009b, Marengoni et al. 2011). However, these studies 
have been carried out among elderly cohorts (mean age approximately 60 to 80 years) and the 
follow-up times have been short (2 to 6 years). Regarding CHD (Aronson et al. 1990, Brayne et 
al. 1998, Ross et al. 1999, Luchsinger et al. 2005, Newman et al. 2005, Hayden et al. 2006, Chen 
et al. 2011) and HF (Qiu et al. 2006) only few previous cohort studies with elderly subjects and 
inconsistent results have investigated the possible association between these diseases and the 
risk of dementia. Thus, our study is the first one to investigate these associations in a cohort 
with a baseline assessment in midlife and a long follow-up time of approximately 25 years. 
Furthermore, we were able to examine heart diseases at different time points in life, thus 
obtaining a more comprehensive picture of the lifelong effect of these heart diseases on the 
subsequent dementia risk.
The mechanisms behind the association between heart diseases and dementia are still un-
clear. There is clear evidence for the role of vascular factors in VaD (Erkinjuntti et al. 2009). This 
seems plausible since VaD is related to stroke and small vessel disease which are undoubtedly 
related to vascular risk factors. Subjects with AF are at a risk of suffering a stroke by throm-
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boembolism which can further predispose to dementia (Lip et al. 2007). AF is known to alter 
hemostatic function by increasing both thrombin generation and fibrin turnover in subjects 
with AF and dementia compared with those without dementia, and long-term use of warfarin, 
an anticoagulant drug, has been postulated to be protective against dementia in patients with 
AF (Barber et al. 2004). Recent data also indicate that HF is associated with an altered hemo-
stasis, namely a prothrombotic state, which can lead to thromboembolic stroke (Davis et al. 
2000). However, the increased risk of both dementia and AD related to late-life AF was seen 
even after adjusting for stroke, i.e. there probably are also some other underlying mechanisms 
involved in the association. It is not currently fully understood how vascular factors contribute 
to the pathogenesis of AD, which is neuropathologically characterized by the deposition of 
amyloid plaques and neurofibrillary tangles in the brain. Interestingly, in animal studies using 
a cholesterol-fed rabbit model of human CHD, both the production and accumulation of intra-
neuronal β-amyloid in the brain was detected in the cholesterol-fed rabbits (Sparks et al. 2000). 
One could argue that the link between heart diseases and AD could be at least partially medi-
ated through cholesterol, as hypercholesterolemia predisposes both to AD and CHD. However, 
the results from clinical studies investigating the role of lipid lowering medication statins in 
reducing the risk of AD have not been consistent (Pac-Soo et al. 2011). In the present study, the 
risk increase related to late-life heart diseases was not changed when including cholesterol 
into the analyses suggesting that other mechanisms might be behind the association. Patients 
with heart diseases often take very limited physical activity and adopt a sedentary lifestyle 
both of which are considered as risk factors for dementia (Rovio et al. 2005). However, in our 
study the increased risk of dementia and AD was observed even after controlling for midlife 
physical activity, as well as for several other midlife and late-life cardiovascular risk factors 
and diseases; therefore, these factors alone do not explain the increased risk of dementia and 
AD related to heart diseases found here.
There are also other common factors between CHD and AD. The major genetic risk factor 
for AD, the APOE ε4 allele, also increases the risk of CHD (Davignon et al. 1988). The vul-
nerability to CHD may be mediated through the increased risk of hypercholesterolemia in 
APOE ε4 carriers. Furthermore, there is evidence to suggest that APOE E4 protein has less 
antioxidant effects than APOE E3 protein (Casserly et al. 2004). As both atherosclerosis and 
AD are associated with increased oxidative stress which is known to contribute to the disease 
pathogenesis, any loss of protective antioxidant factors may exacerbate this kind of damage 
(Markesbery 1997). In addition to oxidative stress, the APOE ε4 allele has been shown to inten-
sify all the biochemical disturbances which are characteristic of AD, i.e. Aβ deposition, tangle 
formation, neuronal cell death, synaptic plasticity, and dysfunctions of lipid homeostasis and 
cholinergic signaling (Cedazo-Minguez et al. 2001). One further common factor in CHD and 
AD is the increased level of inflammation in the body (Akiyama et al. 2000, Hansson 2005). 
Inflammation plays a key role in CHD and in other manifestations of atherosclerosis (Hansson 
2005). Inflammation has also been shown to have a direct role in the initiation, maintenance, 
and recurrence of AF although the underlying mechanisms are unknown (Issac et al. 2007). 
When accumulated over many years, direct and bystander damage from increased inflamma-
tion in the body may exacerbate the pathogenic processes related to AD (Akiyama et al. 2000). 
Still one further interesting putative mechanism mediating the relation between heart dis-
eases and dementia may be associated with the decreased cardiac output which is present in 
several heart diseases, following cerebral hypoperfusion and subsequent neuronal damage 
(de la Torre 2006). In AF, the unsynchronized atrial and ventricular contraction can lead to im-
paired pump function and subsequently to diminished blood flow from the heart to systemic 
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circulation inducing a significant brain hypoperfusion (Gomez et al. 1992). Brain hypoperfu-
sion can be present also in HF, i.e. a condition in which the heart cannot adequately pump 
enough blood to meet the body’s needs (Alves et al. 2005). HF is actually often the end stage of 
CHD and hypertensive heart disease (Kannel 2000), which are also the most common underly-
ing disorders in AF (Krahn et al. 1995). According to one theory, the reduction in the cerebral 
blood flow due to heart diseases may trigger the development of AD pathology in the brain in 
individuals whose cerebral perfusion is already threatened by advanced age (de la Torre 2006). 
Furthermore, chronic brain hypoperfusion may result in a neuronal energy crisis leading in 
defects in protein synthesis that later result in AD neurodegenerative lesions such as the forma-
tion of β-amyloid plaques and neurofibrillary tangles. In one report from the Rotterdam Study, 
low cerebral blood flow was shown to be associated with dementia and also with markers of 
incipient dementia, suggesting that cerebral hypoperfusion precedes and possibly contributes 
to onset of clinical dementia (Ruitenberg et al. 2005). Ultimately, there are several separate 
factors that can affect the neurodegenerative process through various direct and indirect path-
ways and can act in synergistic manner, and in time, result in clinical dementia.
Curiously, AF or CHD diagnosed already in midlife did not have any effect on the later 
dementia risk in the current study. These findings are of special interest, because one might 
expect that the longer a condition predisposing to a disease has time to affect, then greater 
would be the risk. One factor influencing the present findings may be that the number of heart 
disease diagnoses emerging in midlife was quite small. On the other hand, the long follow-
up time between baseline and the diagnosis of dementia may have permitted more effective 
treatment of hypertension and other cardiovascular risk factors along with beneficial changes 
in lifestyle during the follow-up years in subjects with midlife heart diseases, resulting in 
lowered dementia risk. Furthermore, in one large observational study, the increased risk of 
death among demented persons with AF was greatest in the less elderly persons (< 70 years) 
and became non-significant in the older groups (> 80 years) (Bunch et al. 2010). Consequently, 
this lack of association may be due to poorer survival of those demented patients with heart 
diseases, thereby reflecting selective survival. 
We observed that APOE ε4 carriers suffering HF at midlife had an increased risk of de-
mentia and AD. APOE ε4 carriers are known to be more vulnerable to the deleterious effects 
of various risk factors for AD (e.g. alcohol drinking, physical inactivity, and dietary fat intake) 
(Kivipelto et al. 2008). However, when the late-life analyses were stratified by the APOE ε4 
carrier status, a statistically significant increase in dementia risk related to heart diseases was 
observed only among the APOE ε4 non-carriers. This may be due to several factors. First, it 
has been suggested that the effect of APOE ε4 allele on the risk of AD may be attenuated with 
increasing age (Farrer et al. 1997). Thus those subjects with the APOE ε4 allele who survive dis-
ease free until old age may have some other factors (i.e. more effective cell repair mechanisms) 
which protect them from falling ill. Furthermore, because APOE ε4 allele increases the risk of 
CHD as well as the risk of dementia, the lack of association among the APOE ε4 carriers may 
be due to the poorer survival among demented persons with APOE ε4 and heart disease, thus, 
some effect of selective survival cannot be excluded.
This seems to be the first study investigating the association between AF, HF, and CHD 
in midlife and in late-life and how they modulate the subsequent risk of clinically diagnosed 
dementia and AD. The CAIDE study design with its extensive study protocol for diagnos-
ing dementia, as well as the utilization of the excellent register data available from multiple 
sources for defining the heart disease and dementia diagnoses, increases the reliability of 
these findings. It was also possible to control for several putative confounding factors in the 
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analyses. Some effect of survival bias on the results cannot be excluded, but if it does exist it 
would probably underestimate the association between heart diseases and dementia, not the 
opposite. Yet another possible limitation is that although the classification of heart diseases 
was based on self-report and register data, no clinical measurements of AF, HF, or CHD/ath-
erosclerosis were available (e.g. ECG, heart ultrasound). However, the register data is based on 
diagnoses in the national hospital discharge register in Finland which includes information 
on in-patient sojourns in public hospitals, and therefore at least the more severe cases of heart 
diseases leading to hospitalization will be included in the study; the milder cases may have 
been undetected. In the secondary analyses including also the non-participants, the association 
between late-life AF and dementia became diluted. This may be due to a detection bias: there 
may be both undetected heart disease and especially dementia when relying on register data 
only. In the midlife analyses, the number of subjects with heart disease was limited, and thus 
could lead to insufficient power to detect associations.
6.4 METHODOLOGICAL ISSUES
6.4.1 caIde
6.4.1.1 study population and design
The CAIDE study is based on population-based random samples of individuals that were in-
vestigated three times during the study. Participation rates were high, ranging from 77 % to 96 
% at baseline, 72 % at first re-examination, and 63 % at second re-examination. The follow-up 
time of the study was long, on average 28 years at the second re-examination. The prospective 
population-based study design, the long follow-up time of the cohort, and the relatively high 
participation rates all increase the reliability of the findings from this study.
The baseline examinations were conducted in the framework of two large cardiovascular 
studies (the North Karelia Project and the FINMONICA study), neither of which was spe-
cifically designed to investigate cognitive functions or dementia. Thus, no information was 
available on the participants´ cognitive status at baseline. However, at the time of the midlife 
examination subjects were 39 to 64 years old, and it is most unlikely that they would have 
had dementia at that time. However, if there were individuals suffering from early signs of 
dementia already at the baseline examination, they would have probably not survived and 
participated in the re-examinations.
A random sample of survivors of the baseline survey participants was invited to participate 
in CAIDE in 1998. Information about the subjects who had died prior to this first re-examina-
tion was not available at the time of this study, and therefore, the possibility of some survival 
bias must be taken into consideration when interpreting the current results. At the general 
level, the results based on the CAIDE study are applicable to those subjects who survive until 
old age. 
The CAIDE cohort is large enough to allow an investigation of risk factors that are rather 
prevalent in the population, such as smoking, pulmonary and heart diseases investigated here. 
However, the results of some subgroup analyses have to be interpreted with caution, because 
there might be false negative results due to insufficient power. In addition, the number of sub-
jects with types of dementia other than AD was too small to allow any consideration of these 
kinds of dementia types (i.e. VaD) as outcomes in the analyses.
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6.4.1.2 risk factor measurements
The baseline risk factor measurements were made already at midlife, thus, the presence of 
preclinical dementia is unlikely to have influenced these measurements. However, some effect 
of preclinical dementia cannot be excluded in the analyses regarding the association between 
late-life pulmonary and heart diseases and dementia. Information on midlife smoking was 
based on self-report which may have caused some reporting bias. However, if some misreport-
ing regarding information on smoking habits has occurred, it would most probably have been 
about the amount of smoking rather than the smoking status, and thus, ranking of individuals 
into different smoking categories, as conducted here, should be possible. Information on pul-
monary diseases was also based on self-report. In particular, the COPD diagnoses in this study 
may also include some other chronic pulmonary diseases, probably mostly asthma, because 
particularly in the elderly the differentiation between COPD and asthma may be difficult, and 
patients may also display components of both diseases. Therefore, the analyses combining 
both pulmonary diseases were also carried out but they gave comparable results. Furthermore, 
the older a person becomes, the more are factors that can cause shortness of breath (e.g. heart 
diseases) which could have been falsely interpreted as a pulmonary condition, and this may 
have had some effect, especially on the late-life results. With respect to heart diseases, the 
self-reported and register data were combined in order to achieve as accurate information as 
possible on the diagnoses of heart diseases of the participants. However, some reporting bias 
regarding these analyses may still be possible.
 
6.4.1.3 outcome measures
The screening criteria in the first re-examination was based on MMSE, and only subjects with 
MMSE ≤ 24 in the screening phase entered the clinical phase and underwent a more thorough 
investigation of cognitive functions. MMSE may have been sensitive enough to capture mani-
fest AD, but the use of MMSE as the only screening criterion in the first re-examination may 
have resulted in an underdiagnosis of those dementia types in which memory deficits are not 
the main initial manifestation of the disease. In an attempt to improve the sensitivity to detect 
MCI and very mild dementia more criteria were used in the screening phase of the second 
re-examination. These may have also helped in detecting other dementia subtypes beyond 
AD at the second re-examination, as one of the screening criteria was based on report of cog-
nitive decline by the informant, and not simply whether there was any memory impairment. 
It would have been ideal if all of the subjects had participated in both screening and clinical 
phases. However, the three phase protocol was probably adequate in sensitivity and specific-
ity to detect AD since nearly half of all persons evaluated in the clinical phase of the first re-
examination and 60 % of persons evaluated in the clinical phase of the second re-examination 
were nevertheless considered as being cognitively normal. Nearly all of those diagnosed with 
MCI or dementia underwent brain imaging in the differential diagnostic phase. Autopsy data 
were not available to confirm the clinical diagnoses, but a previous neuropathological study 
conducted in our clinic in Kuopio has shown that the accuracy of clinical AD diagnosis is good 
(96 % for probable AD and 86 % for possible AD) (Kosunen et al. 1996).
The diagnosis of MCI in the present study was essentially based on clinical judgement: the 
subjects did not fulfill the criteria for dementia, but had some subjective and objective cogni-
tive impairment. Some cases of MCI and dementia may have been lost due to the MMSE cut-off 
score in the first re-examination. But this has not probably happened very frequently in the 
second re-examination because more screening criteria were used in an attempt to detect also 
milder forms of dementia and MCI. The first re-examination of the CAIDE study was designed 
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to detect dementia, and it is unclear how sensitive and specific this screening procedure was 
in identifying those persons with MCI. However, the prevalence of MCI in the first re-exam-
ination of the CAIDE study was similar to that of another population-based study conducted 
in the same region with a population of corresponding age, suggesting that the detection bias 
was minimal (Hanninen et al. 2002). During the second re-examination, the bias in detecting 
MCI was probably even more reduced.
6.4.1.4 non-participation
Non-participation may have had some influence on these results. There was no information 
available for non-participants in the baseline surveys regarding risk factors or cognitive status. 
However, non-participation rates at baseline were rather low, ranging from 7 % in the cohort 
examined in 1972 to 17 % in the cohort examined in 1987 (Vartiainen et al. 1994). The main 
reasons for non-participation at baseline were: address information not up to date, temporarily 
away from home, or unable to participate; very few individuals actually refused to participate 
in the surveys (Puska et al. 1979).
The role of non-participation at follow-up could be evaluated to some extent. It is com-
monly known that persons with cognitive impairment are less likely to participate in these 
kinds of studies (Launer et al. 1994). The dementia diagnoses of non-participants of the re-
examinations were sought from medical records of local hospitals and health care centres. At 
the time of studies III and IV, also register data on dementia diagnosis of the non-participants 
were available from three different national registers in Finland, and these were additionally 
investigated to obtain more diagnoses. In every study, the main analyses were repeated also 
among the whole study population including the non-participants with dementia diagnoses 
obtained from these other sources in order to estimate the effect of non-participation on the 
results. However, it is known that medical records usually underestimate the prevalence of de-
mentia and so there still might be some cases of dementia missed among the non-participants. 
Nevertheless, as anticipated there were more demented individuals detected among the non-
participants than among the participants in our study. 
The non-participants were more often smokers at midlife than the participants. Thus, if the 
non-participants were at an increased risk of dementia and AD then the present results would 
not overestimate but rather underestimate the true effects of smoking on the risk of dementia 
and AD. The persons who did not participate in any re-examinations had also a higher systolic 
blood pressure, total serum cholesterol level, and BMI values in midlife than the participants. 
Thus, as expected, there were more persons with heart diseases (AF, HF, and CHD) among the 
non-participants (at midlife 10.0 % and at late-life 29.2 %) than among the participants (at midlife 
8.8 % and at late-life 22.8 %). Therefore, if they were also at an increased risk of dementia this 
would result in an underestimation of the true impact of heart diseases on the risk of dementia 
and AD, not the opposite. With respect to pulmonary diseases, there were somewhat more 
persons with asthma and COPD among the non-participants (at midlife 6.8 %) than among 
the participants (at midlife 5.7 %) and if one assumes that they were also at an increased risk 
of cognitive impairment, then the present results would again represent an underestimation 
of the true effect. To evaluate the effect of non-participation the main analyses were repeated 
among the whole study population including also the non-participants in every study, but 
this gave comparable results in studies I and III. In study IV, the associations between late-life 
heart diseases and dementia became diluted when the whole cohort was analyzed. This was 
probably due to detection bias: regardless of utilization of the register data there may still be 
undetected heart disease and especially dementia among the non-participants.
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6.4.1.5 residual confounding
The possibility of bias due to confounding factors was addressed in all studies mainly by ad-
justing the analyses for possible confounders. In addition, some of the analyses were carried 
out separately in subgroups. There was information available on a wide range of sociode-
mographic, lifestyle, and health-related factors. However, there were factors about which no 
information was available, and some of the variables used may have been unable to capture 
all the dimensions of the phenomenon in question. Consequently, the possibility of residual 
confounding cannot be totally excluded. 
6.4.2 Kaiser permanente 
6.4.2.1 study population and design
The second study of the current project was based on a large multiethnic, retrospective study 
cohort of members of the Kaiser Permanente Medical Care Program of Northern California. 
The participants were clinically examined once at midlife during a voluntary health examina-
tion in 1978-1985. The dementia diagnoses of the subjects who were still alive and members 
of the health plan in 1994 were accessed from electronic medical record database between 
January 1st, 1994 and July 31st, 2008. The follow-up time of the study was long, on average 23 
years. The main advantage of retrospective cohort studies in general is the quicker and less 
expensive access to large amounts of information on a variety of risk factors and outcomes. The 
large sample of 21 123 people of both men and women and various ethnic groups along with 
the long follow-up time of the cohort increases the reliability of the findings emerging from 
this study. Moreover, because smoking habits were measured in people aged 50 to 60 years, it 
is unlikely that subclinical dementia would have influenced the results. Although the sample 
is based on health plan members, Kaiser Permanente of Northern California covers more than 
one fourth of the population in the geographic areas it serves, and thus the members are rep-
resentative of the sociodemographics of the local population (Krieger 1992)
6.4.2.2 risk factor measurements
The baseline risk factor measurements were made already at midlife, thus, it is not likely that 
preclinical dementia would have been present then and consequently influenced these meas-
urements. Information on midlife smoking was based on self-report, and thus, some reporting 
bias cannot be excluded. 
6.4.2.3 outcome measures
The large number of persons with dementia diagnoses in the cohort made it possible to evaluate 
the effect of midlife smoking on the risk of both AD and VaD. Since the diagnoses were obtained 
electronically from a medical record database, they are based on ICD-9-CM codes (the ICD-9-CM 
system is currently in use in the US for registering morbidity data). It was not possible to clini-
cally screen all the participants for dementia; it is thus possible that a portion of the population 
may have had undiagnosed dementia. It is also likely that some of the AD or VaD cases were 
missed in those participants who had died before the onset of the ascertainment in 1994. Thus, 
some selective survival effect cannot be ruled out regarding the current results. However, it is 
known that both smoking (de Groot et al. 2004) and cognitive impairment (Stump et al. 2001) 
increase mortality. Accordingly, if it is assumed that among the deceased there were more smok-
ers, and that they were more likely to be demented as well, then the present results would not 
overestimate but rather underestimate the true effects of smoking on the risk of dementia. 
73
Neuropathological data regarding the diagnoses of AD and VaD in the Kaiser Permanente 
cohort was not available. The diagnostic criteria used in current clinical practice are known 
to have a bias towards AD due to the emphasis on memory impairment in the diagnosis of 
dementia. Therefore, there might be some cases of VaD or mixed dementia among those per-
sons diagnosed with AD although the dementia subtypes were diagnosed by a neurologist or 
neuropsychologist in a memory clinic setting. 
6.4.2.4 residual confounding
To reduce the possibility of bias due to confounding factors, the analyses were adjusted for 
various possible confounders. In addition, analyses were carried out separately for those sub-
jects with and without a stroke. A wide range of data on sociodemographic, lifestyle, and 
health-related factors was available for the study. However, it may be not be possible to control 
for some factors about which no information was available, and some of the variables used may 
have been unable to capture all the dimensions of the phenomenon in question. All covariates 
were measured with some inherent inaccuracy, thus leaving the possibility of some residual 
confounding effect. 
74
75
7 Summary and Conclusions
Based on the findings of the present set of studies, the following conclusions can be drawn: 
1)  Midlife smoking is associated with the risk of developing dementia and AD later in 
life especially among those individuals carrying the APOE ε4 allele. These results 
suggest that the association between smoking and AD may be complex and modu-
lated by the genotype. 
2)  Midlife smoking is associated with an increased risk of dementia, AD, and VaD in a 
dose dependent manner; those individuals who smoke more than 2 packs per day in 
middle age are at the greatest risk of developing dementia. The deleterious effects of 
smoking on dementia risk seem to be the same for both genders and to span different 
ethnic groups.
3)  COPD and asthma diagnosed in midlife are associated with the risk of cognitive 
impairment later in life. Pulmonary diseases diagnosed in late-life seem to have an 
inverse relationship with later cognitive impairment; however, this effect may be due 
to survival bias.
4)  Heart diseases, especially atrial fibrillation, diagnosed in late-life are associated with a 
subsequent increased risk of dementia and AD later in life. Heart diseases diagnosed 
already in midlife do not appear to influence the later dementia risk.
76
77
8 Implications and Future Perspectives
The proportion of elderly people in the population is increasing all around the world, and con-
sequently, age-related disorders are also becoming more common. Dementia is one disorder 
whose incidence is highly correlated with age. At the moment there is no curative treatment 
for this disorder. This represents a huge public-health and economic problem as the propor-
tion of elderly persons with dementia is predicted to grow enormously during the next few 
decades. Thus, research into the risk factors and understanding in more detail the etiology 
of dementia and AD, the major form of dementia, are of great importance in the challenge of 
finding potential preventive strategies for the disease.
Recent findings showing that several lifestyle and health-related risk factors may increase 
the risk of dementia and AD has been of special interest because many of these risk factors 
are potentially modifiable. Moreover, it is now appreciated that these factors may affect the 
disease process in the brain already decades before the first clinical symptoms of dementia 
appear. These discoveries coincide with the findings from recent prospective cohort studies 
which have been able to follow-up their subjects for long periods of time. Because of the long 
preclinical phase of AD during which the neuropathological changes evolve in the brain, it is 
essential to examine the time before disease onset in order to reveal the actual factors which 
contribute to the triggering of the disease. The current project has investigated novel risk fac-
tors in two cohort studies with the baseline at midlife and a long follow-up time of over two 
decades for achieving this goal.
Regardless of the well founded awareness of the harmful effects of smoking, this habit is 
still quite common around the world, and even becoming more popular in some developing 
countries. The results of the current study indicate that in addition to increasing the risk of 
heart diseases, pulmonary diseases, and cancer etc. smoking also predisposes to dementia. 
Furthermore, the risk increase may be particularly high in individuals who are genetically 
susceptible to AD. There are also other factors that have been shown to increase the risk of 
dementia especially among the APOE ε4 carriers; for example physical inactivity, dietary fat in-
take, and frequent alcohol drinking at midlife are such factors. The current findings contribute 
to the growing body of evidence that the onset of dementia is a sum of genetic and environ-
mental elements. The APOE ε4 carriers may be more vulnerable to environmental factors, and 
thus, lifestyle interventions may greatly modify dementia risk in these genetically susceptible 
individuals. The present findings also show that the harmful effects of smoking in regard to 
dementia risk are common to both men and women and in different ethnic groups. Promoting 
smoking cessation should be one of the major issues in the public education worldwide; it could 
help to prevent, or at least delay, the onset of dementia, and thus promote living a cognitively 
healthy life also into old age.
COPD and asthma are common pulmonary diseases causing substantial disability world-
wide and COPD is one of the leading global causes of death. Although there is evidence that 
patients with COPD suffer greater cognitive impairment than in healthy persons, these dis-
eases have not been widely studied with regard to the concomitant dementia risk. The current 
results indicate that COPD and asthma diagnosed in midlife may also increase the later risk of 
clinically diagnosed MCI and dementia. However, late-life pulmonary diseases do not predis-
pose to the development of cognitive impairment. It is possible that augmentation of inflamma-
tion and neuronal damage due to the prolonged hypoxemia caused by these chronic diseases 
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contributes to the neurodegenerative process in the brain of subjects who will develop clinical 
dementia or MCI. There are studies which indicate that proper control of asthma in patients 
with cognitive impairment can improve some cognitive functions (Bozek et al. 2010, Bozek et 
al. 2011). Thus, the current findings emphasize the importance of good medical treatment of 
these pulmonary diseases also from the perspective of brain health and cognitive functioning. 
CHD is also one of the leading causes of death around the world. HF is often the end stage 
of CHD and hypertensive heart disease and these are also the most common underlying disor-
ders in AF. As more and more people survive into more advanced ages these heart conditions 
are becoming increasingly common. The influence on the dementia risk of comorbid diseases, 
which do not primarily directly affect the brain, has been recently acknowledged. This has 
opened a new avenue for discovering possible modifiable risk factors for dementia. The results 
of the current project suggest that the persons suffering from these heart diseases in late-life, 
especially from AF, are at an increased risk of developing dementia and AD as well. However, 
there was no relationship between these heart diseases diagnosed at midlife and the risk of 
dementia at late-life, except among the APOE ε4 carriers with heart failure who showed an 
increased risk of AD. Although this may reflect selective survival, it is also possible that the 
long follow-up time between the baseline and the late-life assessment of dementia may have 
enabled more effective treatment of hypertension and other cardiovascular risk factors in con-
junction with beneficial changes in lifestyle during the follow-up years in persons with midlife 
heart diseases, resulting in a lowered dementia risk. These findings emphasize that dementia 
may result from various partly modifiable risk factors, not all necessarily affecting directly 
the brain itself. There is already evidence that treatment of vascular risk factors may slow the 
cognitive decline in AD (Deschaintre et al. 2009). There are also ongoing intervention studies 
focusing on several modifiable risk factors in individuals at risk of developing dementia. These 
studies will provide important information on the crucial question on how well optimal treat-
ment of cardiovascular and other modifiable risk factors can affect the dementia risk and the 
progression rate of the disease. It has been estimated that a 5 year postponement in dementia 
onset would reduce the number of demented persons by 50 % (Brookmeyer et al. 1998). Thus, 
being able to at least delay the onset of dementia by treating the modifiable risk factors could 
have a tremendous effect on the prevalence of dementia in the future.
Previously, various lifestyle related factors have been related to the risk of dementia, but 
now, insights are being made into how these factors affect wellbeing and cognitive health in 
old age already start at least from middle age. There is already some evidence that different 
lifestyle behaviour patterns may be associated with different levels of risk for subsequent de-
mentia, with a generally healthier lifestyle possibly being protective (Norton et al. 2012). Thus, 
one should pay attention to lifestyle already at midlife, because the choices made at that time 
may have long-lasting effects, and may also affect one’s risk of developing dementia in old age. 
With regard to prevention, this is good news. The previous, almost fatalistic, view was that 
AD was mainly induced by genetic risk factors and age. However, recent knowledge about 
the environmental risk factors of the disease provides hope also for genetically susceptible 
individuals; the risk of developing dementia may be lowered by adopting a healthy lifestyle. 
The exact mechanisms of action which mediate the increased disease risk contributable to 
lifestyle and comorbid diseases are not currently known, and these will need to be clarified 
in future studies.
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